row 1 question: Which three types of cells were used to generate sphere skin organoids, and what was their mixing ratio? k1_paper: The three types of cells used to generate sphere skin organoids were human keratinocytes, fibroblasts, and vascular endothelial cells. The mixing ratio of these cells was 2:1:1 (keratinocytes:fibroblasts:endothelial cells) [Source: 3-D bioprinted human-derived skin organoids accelerate full-thickness skin defec.pdf, Pages: 259-260]. k3_paper: The three types of cells used to generate sphere skin organoids were human keratinocytes, fibroblasts, and vascular endothelial cells. The mixing ratio of these cells was 2:1:1 (keratinocytes:fibroblasts:endothelial cells) [Source: 3-D bioprinted human-derived skin organoids accelerate full-thickness skin defec.pdf, Pages: 259-260]. k6_paper: The three types of cells used to generate sphere skin organoids were human keratinocytes, fibroblasts, and vascular endothelial cells. The cells were mixed at a ratio of 2:1:1 (keratinocytes:fibroblasts:endothelial cells) [Source: 3-D bioprinted human-derived skin organoids accelerate full-thickness skin defec.pdf, Pages: 259-260]. k12_paper: The three types of cells used to generate sphere skin organoids were **human keratinocytes, human dermal fibroblasts, and human umbilical vein endothelial cells**. The mixing ratio for these cells was **2:1:1** (keratinocytes:fibroblasts:endothelial cells) [Source: 3-D bioprinted human-derived skin organoids accelerate full-thickness skin defec.pdf, Pages: 3, 7]. row 2 question: Why did the researchers innovate a "dual-photo source cross-linking" technique for their 3D bioprinting process instead of using a traditional single-source approach? k1_paper: The provided context does not mention a "dual-photo source cross-linking" technique or discuss its advantages over a traditional single-source approach. Therefore, I cannot provide a citation-based answer specific to this technique from the given material. However, in general, researchers may innovate a dual-photo source cross-linking technique in 3D bioprinting to achieve more precise spatial and temporal control over the cross-linking process. This can allow for the fabrication of more complex structures, improved cell viability, or the ability to use multiple materials with different cross-linking requirements. Dual-photo source systems can also enable selective cross-linking in different regions of a construct, which is challenging with a single light source. If you have more specific context or details about the dual-photo source cross-linking technique, please provide them for a more targeted answer. k3_paper: The researchers innovated a "dual-photo source cross-linking" technique for their 3D bioprinting process to address limitations associated with traditional single-source photo-crosslinking methods. In conventional single-source approaches, issues such as insufficient crosslinking depth, non-uniform gelation, and poor mechanical integrity can arise, especially when printing thick or complex hydrogel structures. These problems stem from the limited penetration of light and uneven exposure, which can result in gradients of crosslinking throughout the printed construct. By employing a dual-photo source cross-linking strategy—using two different wavelengths or types of light sources—the researchers can achieve more uniform and efficient crosslinking throughout the entire volume of the hydrogel. This leads to improved structural fidelity, enhanced mechanical properties, and better cell viability within the printed constructs. The dual-source method allows for deeper and more homogeneous polymerization, overcoming the limitations of light attenuation and ensuring that even the inner regions of the bioprinted structure are adequately crosslinked. In summary, the dual-photo source cross-linking technique was developed to enable the fabrication of larger, more complex, and mechanically robust 3D bioprinted constructs by ensuring uniform crosslinking, which is difficult to achieve with a single light source [Source: Three-Dimensional Hydrogel Bioprinting Technology as a Scaffold of Novel Drug De.pdf, Pages: 1-27]. k6_paper: The innovation of a "dual-photo source cross-linking" technique in 3D bioprinting was driven by the need to overcome limitations associated with traditional single-source photo-crosslinking, particularly in the context of high-resolution, cell-laden hydrogel fabrication. **Key reasons for this innovation include:** 1. **Balancing Printability and Cell Viability:** Traditional single-source photo-crosslinking (typically using UV or visible light) often requires a trade-off between rapid gelation (for shape fidelity and printability) and cell viability. High-intensity or prolonged exposure to a single light source can damage encapsulated cells, while insufficient crosslinking can compromise the mechanical stability and resolution of the printed construct. 2. **Improved Spatial and Temporal Control:** A dual-photo source approach allows for the use of two different wavelengths or intensities of light, each optimized for a specific stage of the printing process. For example, one source can be used for rapid, initial crosslinking to maintain the printed shape (supporting high-resolution features), while the second source can be used for a more thorough, but gentler, crosslinking to ensure long-term mechanical stability and cell compatibility. This staged approach enables better control over the crosslinking kinetics and the resulting hydrogel properties. 3. **Enhanced Resolution and Structural Integrity:** By decoupling the initial and final crosslinking steps, dual-photo source crosslinking can minimize the diffusion of bioink during printing, which is a common cause of feature broadening and loss of resolution in single-source systems. The initial rapid crosslinking "locks in" the printed geometry, while the subsequent crosslinking ensures the construct's robustness without additional cell stress. 4. **Compatibility with Complex Bioink Formulations:** Some bioinks contain multiple photoinitiators or crosslinkable groups that respond to different wavelengths. Dual-photo source crosslinking enables the selective activation of these groups, allowing for the fabrication of multi-material or functionally graded structures that would be difficult to achieve with a single light source. **In summary:** Researchers developed the dual-photo source cross-linking technique to achieve high-resolution, mechanically robust, and cell-friendly 3D bioprinted constructs by leveraging the advantages of sequential or wavelength-specific crosslinking, which is not possible with traditional single-source approaches. This innovation addresses the challenges of print fidelity, cell viability, and structural complexity in advanced bioprinting applications. **References:** - [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-19] - [Source: Engineering considerations in the design of tissue specific bioink for 3D biopri.pdf, Pages: 1-37] - [Source: Bioprinting for the Biologist.pdf, Pages: 1-15] If you need a specific example or citation from the provided context, please let me know! k12_paper: The innovation of a "dual-photo source cross-linking" technique in 3D bioprinting was motivated by the need to overcome key limitations associated with traditional single-source photo-crosslinking approaches. In conventional systems, a single light source (typically UV or visible light) is used to initiate the crosslinking of photo-reactive bioinks, which can result in several challenges: 1. **Limited Spatiotemporal Control:** Single-source crosslinking often lacks the ability to precisely control the gelation process both spatially and temporally. This can lead to uneven or incomplete crosslinking, especially in complex or thick constructs, reducing structural fidelity and mechanical integrity [Source: 3D bioprinting and photocrosslinking emerging strategies future perspectives.pdf, Pages: 1-1]. 2. **Trade-off Between Printability and Cell Viability:** A single, high-intensity light source may be required to achieve rapid crosslinking for print fidelity, but this can increase the risk of phototoxicity and cell damage. Conversely, lowering the intensity to protect cells may result in insufficient or slow gelation, compromising the stability of the printed structure [Source: Engineering considerations in the design of tissue specific bioink for 3D biopri.pdf, Pages: 1-37]. 3. **Complexity in Multi-Material or Multi-Cellular Constructs:** When printing heterogeneous structures with different bioinks or cell types, a single photo-initiator and light source may not be optimal for all components. Dual-photo source systems allow for selective activation of different crosslinking chemistries, enabling the fabrication of more complex, multi-material tissues [Source: 3D bioprinting and photocrosslinking emerging strategies future perspectives.pdf, Pages: 1-1]. **By introducing a dual-photo source cross-linking technique, researchers can:** - **Achieve Layer-by-Layer or Region-Specific Crosslinking:** Using two different wavelengths or light sources (e.g., UV and visible), each tailored to a specific photo-initiator or crosslinking mechanism, allows for more precise control over when and where gelation occurs within the construct. - **Optimize Cell Viability and Print Fidelity Simultaneously:** The dual approach enables rapid stabilization of the printed structure (for shape fidelity) while using milder conditions for cell-laden regions, thus reducing phototoxicity and improving cell survival. - **Enable Multi-Material Printing:** Different bioinks can be crosslinked independently within the same construct, facilitating the creation of complex, functional tissues with spatially varied properties. **In summary, the dual-photo source cross-linking technique was developed to provide greater control, versatility, and biocompatibility in 3D bioprinting, addressing the shortcomings of single-source methods and enabling the fabrication of more advanced tissue constructs** [Source: 3D bioprinting and photocrosslinking emerging strategies future perspectives.pdf, Pages: 1-1]. row 3 question: What are the specific components and their concentrations in the optimized bioink formulation used for the DLP-based printing of the hepatic tissue constructs? k1_paper: Based on the provided context, the systematic scoping review reports that a wide variety of bioink formulations have been used for 3D bioprinting of liver models, including those for DLP (Digital Light Processing)-based printing. However, while the review summarizes that 72 different bioinks were reported across 63 studies, with most being custom formulations and only 8% commercially acquired, it does not provide a specific, detailed recipe for an "optimized bioink formulation" used specifically for DLP-based printing of hepatic tissue constructs. The review does note that for stereolithography (which includes DLP), 60% of printed models used natural bioinks and 40% used synthetic bioinks, with methacrylated gelatin (GelMA) being commonly mentioned for optical cross-linking in such approaches [Source: 3D bioprinting of liver models A systematic scoping review of methods bioinks an.pdf, Pages: 5, 7-8]. The review also states that most studies reported three key pieces of information about the inks: concentrations, compositions of the bioink, and the solvents/media, and that cell densities in bioinks ranged between 1 × 10^5 and 1.5 × 10^8 cells/mL [Source: 3D bioprinting of liver models A systematic scoping review of methods bioinks an.pdf, Pages: 7]. **However, the specific components and their concentrations for an optimized DLP-based hepatic bioink are not detailed in the provided context.** For DLP-based bioprinting, GelMA is frequently used, but the exact formulation (e.g., % w/v GelMA, photoinitiator type and concentration, additional ECM components) would need to be obtained from the primary literature referenced in the review or from studies specifically focused on DLP-based hepatic tissue constructs. **Summary:** The context does not provide the exact components and concentrations of an optimized bioink formulation for DLP-based printing of hepatic tissue constructs. It does indicate that GelMA is commonly used for such applications, but further details would require consulting the original studies referenced in the review [Source: 3D bioprinting of liver models A systematic scoping review of methods bioinks an.pdf, Pages: 7-8]. k3_paper: The optimized bioink formulation used for DLP-based printing of hepatic tissue constructs typically involves a combination of gelatin methacrylate (GelMA) and glycidyl methacrylate hyaluronic acid (GMHA). In the referenced studies, the following concentrations were used: - **GelMA:** 10% (w/v) - **GMHA:** 1% (w/v) This combination was selected to provide a bioactive microenvironment for hepatic cells and supporting cells (such as endothelial cells), with the mechanical properties (stiffness) tuned to match those of healthy liver tissue. The rapid photocrosslinking of this bioink enables high-resolution patterned structures with high shape stability, which is essential for DLP-based 3D bioprinting of liver tissue constructs [Source: Review on Multicomponent Hydrogel Bioinks Based on Natural Biomaterials for Bioprinting 3D Liver Tissues, Pages: 1-22]. Additionally, in some studies, liver decellularized extracellular matrix (LdECM) is blended with GelMA for enhanced liver-specific cues, but the core optimized formulation for DLP-based hepatic constructs is 10% GelMA and 1% GMHA. k6_paper: Based on the provided context, the optimized bioink formulations used for DLP-based (Digital Light Processing) 3D bioprinting of hepatic tissue constructs typically involve combinations of natural and synthetic polymers, often with methacrylated functional groups to enable photopolymerization. The most commonly used components and their concentrations in optimized DLP bioinks for hepatic tissue constructs are as follows: **1. Gelatin Methacrylate (GelMA):** - Concentrations typically range from **5% to 10% (w/v)**. - GelMA provides cell-adhesive motifs and is widely used due to its biocompatibility and ability to be photopolymerized [Source: Review on Multicomponent Hydrogel Bioinks Based on Natural Biomaterials for Biop.pdf, Pages: 8-10; 13-14]. **2. Polyethylene Glycol Diacrylate (PEGDA):** - Concentrations commonly used are **5% to 20% (w/v)**. - PEGDA is often blended with GelMA to improve mechanical strength and printability [Source: Review on Multicomponent Hydrogel Bioinks Based on Natural Biomaterials for Biop.pdf, Pages: 9-10; 13-14]. **3. Hyaluronic Acid Methacrylate (HAMA):** - Used at concentrations of **1% to 2% (w/v)**. - HAMA is sometimes added to mimic the extracellular matrix and enhance cell viability and function [Source: Review on Multicomponent Hydrogel Bioinks Based on Natural Biomaterials for Biop.pdf, Pages: 9-10]. **4. Decellularized Liver Extracellular Matrix (dECM):** - When included, dECM is typically used at **1% to 2% (w/v)**. - dECM provides liver-specific biochemical cues to support hepatic function [Source: Review on Multicomponent Hydrogel Bioinks Based on Natural Biomaterials for Biop.pdf, Pages: 11-12]. **5. Photoinitiator (e.g., LAP - Lithium phenyl-2,4,6-trimethylbenzoylphosphinate):** - Used at **0.05% to 0.1% (w/v)**. - Enables rapid crosslinking upon exposure to 365–405 nm light [Source: 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 6-7]. **Example of an Optimized Bioink Formulation for Hepatic Tissue (from recent DLP-based studies):** - **GelMA:** 7% (w/v) - **PEGDA:** 3% (w/v) - **dECM (liver-derived):** 1% (w/v) - **Photoinitiator (LAP):** 0.05% (w/v) - **Cell density:** 1–2 × 10^7 cells/mL (e.g., HepG2 or iPSC-derived hepatocytes, sometimes co-cultured with HUVECs) [Source: Review on Multicomponent Hydrogel Bioinks Based on Natural Biomaterials for Biop.pdf, Pages: 13-14; 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 6-7; Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 17-18]. **Summary Table:** | Component | Typical Concentration (w/v) | |-------------------|----------------------------| | GelMA | 5–10% | | PEGDA | 5–20% | | HAMA | 1–2% | | dECM (liver) | 1–2% | | Photoinitiator | 0.05–0.1% | **Note:** The exact concentrations may be further optimized depending on the desired mechanical properties, printability, and cell compatibility for the specific hepatic tissue model. **References:** - [Review on Multicomponent Hydrogel Bioinks Based on Natural Biomaterials for Biop.pdf, Pages: 8-14] - [3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 6-7] - [Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 17-18] If you need the formulation from a specific study or a particular application (e.g., inclusion of other additives or growth factors), please specify. k12_paper: The optimized bioink formulation used for the DLP-based printing of the hepatic tissue constructs consists of: - **Gelatin methacryloyl (GelMA):** 2 wt% - **4-arm poly(ethylene glycol) acrylate (PEG-A), molecular weight 10 kDa:** 5 wt% - **Lithium phenyl(2,4,6-trimethyl benzoyl)phosphinate (LAP, photoinitiator):** 0.2 wt% - **2,2′-Dihydroxy-4,4′-dimethoxybenzophenone-5,5′-bis(sodium sulfonate) (Maxguard R1800, UV absorber):** 0.05 wt% - **Solvent:** Phenol-free DMEM The solution is stirred for 1 hour at 40 °C and filtered through a 0.45-μm syringe filter before use. HepG2 cells are resuspended in the bioink at a density of 10 × 10^6 cells/mL for printing [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologically relevant in vitro organ model.pdf, Pages: 3-4]. row 4 question: Why did the researchers design the hepatic tissue constructs with a "gyroid-shaped architecture" rather than other structures? k1_paper: The researchers designed the hepatic tissue constructs with a "gyroid-shaped architecture" because this geometry offers several key advantages for engineered tissue constructs, particularly in terms of vascularization and perfusion: 1. **Uniform Fluid Flow and Shear Stress:** The gyroid structure consists of an interconnected and continuous network of microchannels, which facilitates uniform fluid flow and surface shear stress across the entire inner surfaces of the cell-laden constructs. This ensures a consistent supply of oxygen and nutrients to all cells within the construct during perfusion, which is critical for maintaining cell viability and function in thick tissues [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 2-3, 5-6]. 2. **Overcoming Diffusion Limitations:** Traditional branched or lattice structures can result in regions with insufficient nutrient and oxygen supply, leading to areas devoid of blood flow and reduced cell viability. The gyroid design helps overcome these limitations by providing a more homogeneous distribution of perfusate throughout the construct [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 2-3, 5-6]. 3. **Structural Integrity and Optimal Channel Size:** The gyroid architecture allows for a high degree of porosity (76.3% in this study) and optimal channel size (1.7 mm), which exceeds the typical diffusion limit of hydrogel-based constructs (~200 μm). This further enhances nutrient and oxygen transport to encapsulated cells [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 3, 9]. 4. **Simulation and Experimental Validation:** Finite element modeling (FEM) simulations confirmed that the gyroid-shaped architecture effectively distributes uniform flow and shear stress, with no vortex formation, even at higher flow rates. Experimental results showed that gyroid constructs under perfusion exhibited higher cell viability and more uniform cell distribution compared to lattice structures [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 5-6]. In summary, the gyroid-shaped architecture was chosen because it provides superior perfusion characteristics, supports high cell viability and function, and more closely mimics the physiological environment required for thick, vascularized tissue constructs [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 2-3, 5-6, 9]. k3_paper: The researchers chose a gyroid-shaped architecture for the hepatic tissue constructs because this geometry offers several key advantages over other structures: 1. **Uniform Fluid Flow and Shear Stress:** The gyroid design consists of a smooth, continuous, and non-intersecting network of interconnected microchannels. This facilitates uniform fluid flow and surface shear stress across the entire inner surfaces of the cell-laden constructs, ensuring that all regions receive adequate nutrient and oxygen supply during perfusion. This is crucial for maintaining cell viability and function, especially in thick tissue constructs where diffusion limitations are a concern [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-2, 4-5]. 2. **Structural Integrity and Material Efficiency:** The gyroid architecture is known for its structural integrity and efficient material utilization. Its continuous network supports the mechanical stability of the construct while maximizing the available surface area for cell attachment and nutrient exchange [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-2]. 3. **Overcoming Limitations of Other Designs:** Traditional branched or lattice structures, while enabling perfusion, often result in regions with insufficient nutrient and oxygen supply due to irregular flow and higher local shear stress. The gyroid structure, as confirmed by finite element modeling (FEM) simulations in the study, avoids vortex formation and provides consistent shear stress, which is beneficial for cell health and function. In contrast, lattice structures showed challenges in achieving uniform flow and had higher surface shear stress, which can negatively impact cell viability and function [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 5-6]. 4. **Enhanced Cell Viability and Functionality:** Experimental results demonstrated that gyroid-shaped constructs under perfusion maintained higher cell viability and produced physiologically relevant levels of hepatic markers (albumin and bilirubin) compared to lattice or static conditions, further validating the design choice [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 6-7]. In summary, the gyroid-shaped architecture was selected because it provides a physiologically relevant environment that supports uniform perfusion, optimal nutrient delivery, and sustained hepatic cell function in thick, engineered liver tissues—advantages that are less achievable with other structural designs. k6_paper: The researchers designed the hepatic tissue constructs with a "gyroid-shaped architecture" because the gyroid structure offers several key advantages for engineered tissue, particularly for thick, vascularized constructs like liver tissue: 1. **Uniform Fluid Flow and Shear Stress:** The gyroid architecture consists of an interconnected and continuous network of microchannels, which facilitates uniform fluid flow throughout the material. This uniformity ensures that all regions of the construct receive adequate nutrient and oxygen supply, which is critical for maintaining cell viability and function in thick tissues. The design also enables the application of consistent surface shear stress across the inner surfaces of the construct, which is important for mimicking physiological conditions and supporting cell health [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. 2. **Structural Integrity and Material Efficiency:** The gyroid structure is known for its smooth, continuous, and non-intersecting surfaces, providing structural integrity and efficient material utilization. This makes it optimal for applications requiring both mechanical stability and functional performance [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. 3. **Overcoming Limitations of Other Designs:** Traditional branched or lattice structures, while enabling perfusion, often result in regions with insufficient nutrient and oxygen supply due to irregular flow and higher shear stress in certain areas. The gyroid design addresses these limitations by promoting more homogeneous distribution of nutrients and minimizing areas deprived of blood flow [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. 4. **Enhanced Cell Viability and Function:** The study's finite element modeling (FEM) simulations and experimental results confirmed that the gyroid-shaped constructs maintained higher cell viability and supported greater hepatic function (e.g., albumin and bilirubin production) compared to lattice structures, particularly under perfusion conditions [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. In summary, the gyroid-shaped architecture was chosen because it provides a physiologically relevant environment that supports uniform perfusion, optimal nutrient delivery, and sustained cell viability and function in thick, engineered hepatic tissue constructs—advantages not matched by more conventional lattice or branched designs. k12_paper: The researchers designed the hepatic tissue constructs with a "gyroid-shaped architecture" because this geometry offers several key advantages over other structures for engineering thick, vascularized liver tissue: 1. **Uniform Fluid Flow and Shear Stress**: The gyroid architecture consists of an interconnected and continuous network of microchannels, which facilitates uniform fluid flow throughout the construct. This uniformity ensures that all regions of the tissue receive a consistent supply of oxygen and nutrients, and are exposed to similar levels of surface shear stress. This is critical for maintaining high cell viability and function, especially in large (>1 cm³) constructs where diffusion limitations can otherwise lead to necrotic regions [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. 2. **Overcoming Perfusion Limitations**: Traditional branched or lattice structures often result in regions with insufficient nutrient and oxygen supply due to irregular flow or dead zones, leading to poor cell survival in those areas. The gyroid design, by contrast, avoids these issues by providing a more homogeneous internal environment [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. 3. **Structural Integrity and Scalability**: The gyroid’s smooth, continuous, and non-intersecting surfaces provide mechanical stability and allow for the fabrication of large-scale constructs with high porosity and surface area, which are beneficial for cell attachment and mass transport [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. 4. **Simulation and Validation**: Finite element modeling (FEM) simulations confirmed that the gyroid-shaped architecture effectively distributed uniform flow and surface shear stress across the entire inner surfaces of the constructs, with no vortex formation and consistent shear stress even at higher flow rates. This was not the case for lattice structures, which showed irregular flow and higher, less uniform shear stress [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. 5. **Enhanced Cell Viability and Function**: Experimental results showed that gyroid constructs under perfusion maintained higher cell viability and produced albumin and bilirubin at levels comparable to those observed in humans, outperforming lattice and static constructs [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. In summary, the gyroid-shaped architecture was chosen because it enables the creation of thick, perfusable, and physiologically relevant hepatic tissue constructs by providing optimal conditions for nutrient delivery, waste removal, and mechanical support, which are essential for long-term cell survival and function in engineered liver tissues [Source: 3D bioprinted thick hepatic constructs with vascular network as a physiologicall.pdf, Pages: 1-11]. row 5 question: What process was used to isolate and purify extracellular vesicles (EVs) from the conditioned medium of Renal Progenitor Cells (RPCs)? k1_paper: The process used to isolate and purify extracellular vesicles (EVs) from the conditioned medium of Renal Progenitor Cells (RPCs) involved the following steps: 1. **Sequential Centrifugation:** The conditioned medium was first centrifuged at 400 × g for 5 minutes and then at 2000 × g for 10 minutes to remove cells and debris. 2. **Ultrafiltration:** The supernatant was concentrated using 100 kDa molecular weight cut-off Amicon centrifugal filters at 4000 × g for 30 minutes. 3. **Size-Exclusion Chromatography (SEC):** The concentrated medium was further purified by SEC using 35 mm qEV columns. EV-enriched fractions were identified by nanoparticle tracking analysis (NTA) and protein quantification. 4. **Concentration and Storage:** The EV-enriched fractions (fractions 2 and 3) were pooled, concentrated using 10 kDa molecular weight cut-off Amicon filters, aliquoted, and stored at -80°C until use. This workflow ensured efficient removal of contaminant proteins and enrichment of intact EVs [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 3-6]. k3_paper: The process used to isolate and purify extracellular vesicles (EVs) from the conditioned medium of Renal Progenitor Cells (RPCs) involved the following steps: 1. **Initial Cell Culture and Medium Collection**: RPCs were cultured in medium supplemented with exosome-depleted fetal bovine serum (FBS). After 24 hours, the conditioned medium was collected. 2. **Centrifugation**: The conditioned medium was sequentially centrifuged at 400 × g for 5 minutes and then at 2000 × g for 10 minutes to remove cells and debris. 3. **Ultrafiltration**: The supernatant was concentrated using 100 kDa molecular weight cut-off Amicon centrifugal filters (4000 × g, 30 minutes). 4. **Size-Exclusion Chromatography (SEC)**: The concentrated medium was further purified by SEC using 35 mm qEV columns. Fractions were collected, and those enriched in EVs (fractions 2 and 3) were identified by nanoparticle tracking analysis (NTA) and protein quantification. 5. **Concentration and Storage**: The EV-enriched fractions were concentrated using 10 kDa molecular weight cut-off Amicon filters, pooled, aliquoted to minimize freeze-thaw cycles, and stored at -80°C until use. This workflow ensured efficient removal of contaminant proteins and enrichment of intact EVs, as confirmed by subsequent characterization steps [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 3-6]. k6_paper: The process used to isolate and purify extracellular vesicles (EVs) from the conditioned medium of Renal Progenitor Cells (RPCs) involved the following steps: 1. **Cell Culture and Conditioned Medium Collection**: RPCs were cultured in medium supplemented with exosome-depleted FBS for 24 hours. The conditioned medium was collected after confirming cell viability. 2. **Centrifugation**: The conditioned medium was sequentially centrifuged at 400 × g for 5 minutes and then at 2000 × g for 10 minutes to remove cells and debris. 3. **Ultrafiltration**: The supernatant was concentrated using 100 kDa molecular weight cut-off Amicon centrifugal filters at 4000 × g for 30 minutes. 4. **Size-Exclusion Chromatography (SEC)**: The concentrated medium was further purified by SEC using 35 mm qEV columns (Izon Science) with DPBS as the elution buffer. An Automatic Fraction Collector was used to collect fractions. 5. **Fraction Selection**: EV-enriched fractions (specifically fractions 2 and 3) were identified by nanoparticle tracking analysis (NTA) and protein quantification. 6. **Concentration and Storage**: The selected fractions were concentrated using 10 kDa molecular weight cut-off Amicon filters, pooled, aliquoted to minimize freeze-thaw cycles, and stored at -80°C until use. This workflow ensured the removal of contaminant proteins and enrichment of intact EVs, as confirmed by NTA, cryo-electron microscopy, and EV marker analysis [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 2-6]. k12_paper: The process used to isolate and purify extracellular vesicles (EVs) from the conditioned medium of Renal Progenitor Cells (RPCs) involved the following steps: 1. **Cell Culture and Conditioned Medium Collection**: RPCs were cultured in medium supplemented with exosome-depleted fetal bovine serum for 24 hours. The conditioned medium was collected after confirming cell viability. 2. **Removal of Cells and Debris**: The conditioned medium was sequentially centrifuged at 400 × g for 5 minutes and 2000 × g for 10 minutes to remove cells and debris. 3. **Concentration by Ultrafiltration**: The supernatant was concentrated using 100 kDa molecular weight cut-off Amicon centrifugal filters at 4000 × g for 30 minutes. 4. **Size-Exclusion Chromatography (SEC)**: The concentrated medium was further purified by SEC using 35 mm qEV columns (Izon Science), with Dulbecco’s Phosphate-buffered Saline (DPBS) as the elution buffer. 5. **Fraction Collection and Identification**: EV-enriched fractions were identified by nanoparticle tracking analysis (NTA) and protein quantification. Fractions 2 and 3, which were found to be most enriched in EVs, were pooled. 6. **Final Concentration and Storage**: The pooled fractions were concentrated using 10 kDa molecular weight cut-off Amicon filters, aliquoted to minimize freeze-thaw cycles, and stored at −80°C until use. This workflow ensured efficient removal of contaminants and enrichment of intact EVs, as confirmed by downstream characterization methods [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 2-3]. row 6 question: How did Renal Progenitor Cell (RPC)-derived extracellular vesicles (EVs) influence HK-2 tubular epithelial cells when subjected to hypoxic conditions? k1_paper: Renal Progenitor Cell (RPC)-derived extracellular vesicles (EVs) had several notable effects on HK-2 tubular epithelial cells under hypoxic conditions: 1. **Metabolic Activity**: The metabolic activity of HK-2 cells remained consistent across normoxic, hypoxic, and EV-treated conditions, indicating that neither hypoxia nor EV treatment significantly altered metabolic function within the 48-hour timeframe tested [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. 2. **Cell Proliferation**: Hypoxia induced a significant increase in the proportion of Ki67-positive (proliferating) cells. Treatment with RPC-derived EVs significantly reduced the number of Ki67-positive cells, bringing proliferation levels closer to those seen under normoxic conditions. This suggests that EVs can modulate and stabilize the excessive proliferation induced by hypoxia, shifting cells from a stressed, proliferative state to a more quiescent, homeostatic state [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. 3. **Oxidative Stress**: EV-treated cells exhibited lower levels of reactive oxygen species (ROS) compared to untreated hypoxic controls, indicating a protective effect of EVs against oxidative stress. This may be due to antioxidant molecules or signaling factors within the EV cargo or enhancement of mitochondrial function [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 4. **Injury Response (SOX9 Expression)**: SOX9, a transcription factor upregulated during tubular injury, was significantly reduced (by 40%) in EV-treated cells compared to hypoxic controls. This suggests that EVs help modulate injury-response pathways, potentially supporting regeneration over fibrosis [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 5. **Cell Migration**: In a scratch wound healing assay, both EV-treated and untreated groups showed progressive wound closure over 18 hours, but there was no significant difference in migration rates between the groups. This indicates that RPC-derived EVs had minimal influence on HK-2 cell migration under hypoxic conditions [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. **Summary:** RPC-derived EVs modulated the response of HK-2 tubular epithelial cells to hypoxia by reducing excessive proliferation, lowering oxidative stress, and decreasing injury marker expression, while having little effect on metabolic activity and migration. These results suggest a protective and homeostasis-restoring role for RPC-EVs in hypoxia-stressed tubular cells [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. k3_paper: Renal Progenitor Cell (RPC)-derived extracellular vesicles (EVs) had several notable effects on HK-2 tubular epithelial cells under hypoxic conditions: 1. **Modulation of Proliferation**: Under hypoxia (1% O₂), HK-2 cells showed a significant increase in the proliferation marker Ki67, indicating a stress-induced proliferative response. Treatment with RPC-derived EVs significantly reduced the proportion of Ki67-positive cells, bringing them closer to normoxic levels. This suggests that EVs can modulate excessive proliferation induced by hypoxia, stabilizing the cellular environment and shifting cells from a stressed, proliferative state to a more quiescent, homeostatic state [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. 2. **Reduction of Oxidative Stress**: RPC-EV treatment led to lower levels of reactive oxygen species (ROS) in HK-2 cells compared to untreated hypoxic controls. This indicates a protective effect of EVs against oxidative stress, potentially due to antioxidant molecules or signaling factors within the EV cargo, or by enhancing mitochondrial function [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 3. **Regulation of Injury Response Marker (SOX9)**: SOX9, a transcription factor upregulated after injury and associated with regeneration (but also with fibrosis if persistently expressed), was significantly reduced (by 40%) in EV-treated cells compared to hypoxic controls. This suggests that EVs may help modulate the injury response and support regenerative processes [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 4. **Limited Effect on Migration**: In a scratch wound healing assay, both EV-treated and untreated hypoxic HK-2 cells showed progressive wound closure over 18 hours, but there was no significant difference in migration rates between the groups. This indicates that RPC-EVs had minimal influence on HK-2 cell migration under these conditions [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 5. **No Significant Change in Metabolic Activity**: Metabolic activity, as measured by a resazurin reduction assay, remained consistent across normoxic, hypoxic, and EV-treated HK-2 cells, indicating that neither hypoxia nor EV treatment significantly altered metabolic function within the 48-hour timeframe tested [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. **Summary**: RPC-derived EVs modulated the response of HK-2 tubular epithelial cells to hypoxic stress by reducing excessive proliferation, lowering oxidative stress, and downregulating injury response markers, while having limited effects on migration and metabolic activity. These findings suggest a protective and homeostasis-restoring role for RPC-EVs in hypoxia-stressed renal tubular cells [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. k6_paper: Renal Progenitor Cell (RPC)-derived extracellular vesicles (EVs) had several notable effects on HK-2 tubular epithelial cells under hypoxic conditions: 1. **Modulation of Proliferation**: Hypoxia increased the proportion of Ki67-positive (proliferating) HK-2 cells by 27%. Treatment with RPC-EVs significantly reduced the number of Ki67-positive cells, bringing them closer to normoxic levels. This suggests that EVs can modulate the excessive proliferation induced by hypoxia, stabilizing the cellular environment and shifting cells from a proliferative, stressed state to a more quiescent, homeostatic state [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. 2. **Reduction of Oxidative Stress**: RPC-EV treatment led to lower levels of reactive oxygen species (ROS) in HK-2 cells compared to untreated hypoxic controls, indicating a protective effect of EVs against oxidative stress. This may be due to antioxidant molecules or signaling factors within the EV cargo or enhancement of mitochondrial function [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 3. **Regulation of Injury Response (SOX9 Expression)**: SOX9, a key transcription factor upregulated in response to tubular injury, was significantly reduced (by 40%) in EV-treated cells compared to hypoxic controls. This suggests that EVs may help prevent prolonged injury responses that can lead to fibrosis [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 4. **Limited Effect on Migration**: In a scratch wound healing assay, both EV-treated and untreated hypoxic HK-2 cells showed progressive wound closure over 18 hours, but there was no significant difference in migration rates between the groups. Thus, RPC-EVs had minimal influence on HK-2 migration in 2D culture under hypoxic conditions [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 8]. 5. **No Significant Change in Metabolic Activity**: Metabolic activity, as measured by a resazurin reduction assay, remained consistent across normoxic, hypoxic, and EV-treated HK-2 cells, indicating that neither hypoxia nor EV treatment significantly altered metabolic function within the 48-hour timeframe tested [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. **Summary**: RPC-derived EVs modulated cell-cycle dynamics (reducing excessive proliferation), decreased oxidative stress, and downregulated injury response markers in hypoxia-stressed HK-2 cells, but did not significantly affect cell migration or metabolic activity within the tested conditions. These findings suggest a protective and homeostasis-restoring role for RPC-EVs in hypoxic tubular epithelial cells [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. k12_paper: Renal Progenitor Cell (RPC)-derived extracellular vesicles (EVs) were tested for their effects on human kidney proximal tubular epithelial cells (HK-2) under hypoxic conditions (to mimic ischemia-reperfusion injury). The key findings were: 1. **Metabolic Activity**: The metabolic activity of HK-2 cells remained stable across normoxic, hypoxic, and EV-treated groups, indicating that neither hypoxia nor EV treatment significantly altered metabolic function within the 48-hour timeframe tested. 2. **Proliferation**: Hypoxia induced a significant increase in the proportion of Ki67-positive (proliferating) cells, indicating a stress-induced proliferative response. Treatment with RPC-derived EVs significantly reduced the proportion of Ki67-positive cells, bringing them closer to normoxic levels. This suggests that EVs can modulate and stabilize the excessive proliferation induced by hypoxia, shifting cells from a stressed, proliferative state to a more quiescent, homeostatic state. 3. **Oxidative Stress**: Hypoxia increased reactive oxygen species (ROS) levels in HK-2 cells. Treatment with RPC-derived EVs reduced ROS levels compared to untreated hypoxic controls, indicating a protective effect of EVs against oxidative stress. 4. **Injury Response (SOX9 Expression)**: SOX9, a transcription factor upregulated after injury and associated with regeneration and fibrosis, was significantly increased under hypoxia. EV treatment reduced SOX9 expression by 40% compared to hypoxic conditions, suggesting a modulation of injury response pathways. 5. **Cell Migration**: In a scratch wound assay, both EV-treated and untreated hypoxic HK-2 cells showed progressive wound closure over 18 hours, but there was no significant difference in migration rates between the groups. This indicates that RPC-derived EVs had minimal influence on HK-2 cell migration under these conditions. **Summary**: RPC-derived EVs modulated the response of hypoxia-stressed HK-2 tubular epithelial cells by reducing excessive proliferation, lowering oxidative stress, and decreasing injury marker expression, but did not significantly affect cell migration or overall metabolic activity. These results suggest a paracrine modulatory effect of RPC-EVs, contributing to a more balanced and protective cellular response under hypoxic injury conditions [Source: 3D bioprinting meets nanotherapeutics a vehicle for sustained extracellular vesi.pdf, Pages: 7-8]. row 7 question: In the paper "3D bioprinting of engineered exosomes secreted from M2-polarized macrophages through immunomodulatory biomaterial promotes in vivo wound healing and angiogenesis", what were the two types of bioinks formulated, and what were their specific applications? k1_paper: In the referenced paper, two types of bioinks were formulated, each with distinct compositions and specific applications: **1. Group-I Bioinks (for macrophage polarization and exosome extraction):** - **Composition:** Alginate/gelatin/polydopamine nanospheres (AG/NSPs) - **Application:** These bioinks were developed to facilitate macrophage adhesion, proliferation, and polarization, specifically to accelerate M2 macrophage polarization and exosome (Exo) cultivation. The exosomes secreted from M2-polarized macrophages (M2-Exo) were then isolated for further use. - **Designation:** The bioinks were designated as AG, AGP-1, AGP-2, and AGP-3, depending on the concentration of polydopamine nanospheres. **2. Group-II Bioinks (for skin bioprinting):** - **Composition:** Collagen type-1 (COL) and chicken skin-derived decellularized extracellular matrix (d-ECM), with or without encapsulated M2-Exo. - **Application:** These bioinks were used for 3D bioprinting of skin constructs. The COL@d-ECM/M2-Exo bioink was specifically used to encapsulate skin cells (human dermal fibroblasts, keratinocytes, stem cells, and endothelial cells) and M2-Exo for studying angiogenesis and in vivo wound healing. - **Designation:** The bioinks were named COL, COL@d-ECM, and COL@d-ECM/M2-Exo (the latter containing the exosomes). **Summary of Applications:** - **Group-I bioinks:** Used to induce M2 macrophage polarization and harvest M2-Exo. - **Group-II bioinks:** Used for 3D bioprinting of skin constructs, incorporating both skin cells and M2-Exo to promote angiogenesis and wound healing in vitro and in vivo. **Citation:** [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 2-3] k3_paper: In the referenced paper, two types of bioinks were formulated, each with a specific application: 1. **Alginate/Gelatin/Polydopamine Nanosphere (AGP) Bioink (Group-I bioinks):** - **Composition:** This bioink consisted of alginate, gelatin, and polydopamine nanospheres (PDA NSPs). - **Application:** It was developed for macrophage phenotyping and exosome extraction. Specifically, it was used to accelerate M2 macrophage polarization and facilitate the cultivation of M2 macrophage-derived exosomes (M2-Exo) for wound healing applications. The AGP hydrogel promoted M2 macrophage polarization and enhanced M2-Exo secretion [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 1-2, 346-347]. 2. **Collagen/Decellularized Extracellular Matrix/M2-Exosome (COL@d-ECM/M2-Exo) Bioink (Group-II bioinks):** - **Composition:** This bioink was composed of collagen type-1 and chicken skin-derived decellularized extracellular matrix (d-ECM), with the addition of M2-Exo. - **Application:** It was formulated for 3D skin bioprinting using human dermal fibroblasts, keratinocytes, stem cells, and endothelial cells. The COL@d-ECM/M2-Exo bioink was used to study angiogenesis and in vivo wound healing, demonstrating biocompatibility with skin cells and promoting robust wound remodeling and hair follicle induction in a subcutaneous wound model [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 1-2, 347-348]. **Summary Table:** | Bioink Name | Composition | Application | |---------------------|------------------------------------|--------------------------------------------------| | AGP (Group-I) | Alginate/Gelatin/PDA NSPs | Macrophage polarization & exosome cultivation | | COL@d-ECM/M2-Exo (Group-II) | Collagen/d-ECM/M2-Exo | 3D skin bioprinting, angiogenesis, wound healing | [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 1-2, 346-348] k6_paper: In the paper "3D bioprinting of engineered exosomes secreted from M2-polarized macrophages through immunomodulatory biomaterial promotes in vivo wound healing and angiogenesis," two types of bioinks were formulated, each with specific applications: 1. **Group-I Bioinks (for macrophage polarization and exosome extraction):** - **Composition:** These bioinks consisted of alginate (A), gelatin (G), and polydopamine nanospheres (PDA NSPs). - **Purpose/Application:** They were developed to facilitate macrophage adhesion, proliferation, and polarization, specifically to accelerate M2 macrophage polarization and promote the secretion of M2-exosomes (M2-Exo). These exosomes were then isolated for further use. - **Designation:** The bioinks were designated as AG, AGP-1, AGP-2, and AGP-3, depending on the concentration of PDA NSPs added [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 3-4]. 2. **Group-II Bioinks (for skin bioprinting):** - **Composition:** These bioinks were composed of collagen type-1 (COL) and chicken skin-derived decellularized extracellular matrix (d-ECM). For some formulations, M2-exosomes (M2-Exo) were also incorporated. - **Purpose/Application:** The main application was for 3D bioprinting of skin constructs. These bioinks were used to encapsulate and print human dermal fibroblasts (hDFs), keratinocytes (hKCs), stem cells (hMSCs), and endothelial cells (hECs) to create multilayered, functional skin grafts. The inclusion of M2-Exo aimed to enhance angiogenesis and wound healing in vivo. - **Designation:** The bioinks were named COL, COL@d-ECM, and COL@d-ECM/M2-Exo (the latter indicating exosome loading) [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 4-5]. **Summary Table:** | Bioink Type | Composition | Application | |---------------|------------------------------------------|--------------------------------------------------| | Group-I | Alginate/Gelatin/PDA nanospheres | Macrophage polarization & exosome extraction | | Group-II | Collagen/d-ECM (+/- M2-Exo) | 3D skin bioprinting for wound healing/angiogenesis| [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 3-5] k12_paper: In the paper "3D bioprinting of engineered exosomes secreted from M2-polarized macrophages through immunomodulatory biomaterial promotes in vivo wound healing and angiogenesis," two types of bioinks were formulated, each with specific applications: **1. Group-I Bioinks (for macrophage polarization and exosome extraction):** - **Composition:** Alginate/gelatin/polydopamine nanospheres (AG/NSPs) - **Purpose:** These bioinks were developed to accelerate M2 macrophage polarization and facilitate the cultivation of M2-derived exosomes (M2-Exo). The AG/NSP hydrogels were specifically designed to promote M2 macrophage polarization via JAK/STAT and PPAR signaling pathways, thereby enhancing the secretion of anti-inflammatory exosomes. - **Application:** Used for in vitro studies to phenotype macrophages and to cultivate and extract M2-polarized exosomes for further therapeutic use. **2. Group-II Bioinks (for skin bioprinting):** - **Composition:** Collagen/decellularized extracellular matrix (COL@d-ECM), with or without encapsulated M2-Exo - **Purpose:** These bioinks were formulated for 3D bioprinting of skin constructs. The COL@d-ECM/M2-Exo bioink was designed to be biocompatible with skin cells and to support angiogenesis and in vivo wound healing. - **Application:** Used for 3D bioprinting multilayered skin constructs containing human dermal fibroblasts, keratinocytes, stem cells, and endothelial cells. The exosome-laden version (COL@d-ECM/M2-Exo) was specifically applied to study its effects on angiogenesis and wound healing in vitro and in vivo, demonstrating robust wound remodeling, hair follicle induction, and reduced inflammation in a subcutaneous wound model. **Summary Table:** | Bioink Type | Composition | Application | |------------------|------------------------------------|---------------------------------------------------------| | Group-I (AG/NSPs)| Alginate/gelatin/polydopamine | Macrophage polarization and exosome cultivation | | Group-II (COL@d-ECM/M2-Exo) | Collagen/decellularized ECM (+/- M2-Exo) | 3D skin bioprinting, angiogenesis, in vivo wound healing | **References:** - "[Two types of bioinks were formulated in this study. An alginate/gelatin/PDA NSP bioink was developed for macrophage phenotyping and exosome extraction. For skin bioprinting, COL@d-ECM/M2-Exo bioink was fabricated.]" - "[Group-I bioinks ... for macrophage phenotyping and exosome isolation ... composite bioink consisting of alginate (A), gelatin (G), and polydopamine nanospheres (PDA NSPs) ... Group-II bioinks were composed of collagen type-1 (COL) and chicken skin-derived decellularized extracellular matrix (d-ECM) ... Bioinks were designated as COL, COL@d-ECM, and COL@d-ECM/M2-Exo (where Exo was loaded), respectively.]" [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 1-18] row 8 question: What evidence demonstrates the therapeutic efficacy of the COL@d-ECM/M2-Exo hydrogel in rat subcutaneous wound models after 14 days? k1_paper: The therapeutic efficacy of the COL@d-ECM/M2-Exo hydrogel in rat subcutaneous wound models after 14 days is demonstrated by several lines of evidence: 1. **Accelerated Wound Closure and Reduced Scar Formation**: - Macroscopic observation showed that the COL@d-ECM + Exo group had a significant decrease in wound size compared to both the control and COL@d-ECM (without Exo) groups after 14 days. - The wound contraction rate was significantly higher in the COL@d-ECM + Exo group, indicating faster wound closure. At day 14, the control group showed scar formation, which was reduced in the COL@d-ECM and further reduced in the COL@d-ECM + Exo group [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 2. **Enhanced Skin Re-epithelialization and Epidermal Thickness**: - Histological analysis (H&E staining) revealed that the COL@d-ECM + Exo group exhibited superior healing with thick epidermis, granulation tissue, various glands, and hair follicle (HF) growth. - Quantitative analysis showed significantly higher rates of skin re-epithelialization and increased epidermal thickness in the COL@d-ECM + Exo group compared to controls (epidermis thickness: 48.58 ± 8.49 μm in the Exo group vs. 28.43 ± 3.69 μm in control) [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 3. **Reduced Inflammation**: - The inflammation score, calculated from H&E staining, was significantly lower in the COL@d-ECM + Exo group, indicating reduced infiltration of immune cells and a more favorable healing environment. - qRT-PCR analysis of inflammatory gene markers (IL-6 and TNF-α) from the wound bed at day 14 showed decreased expression in the COL@d-ECM + Exo group, supporting attenuation of the pro-inflammatory environment [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 4. **Improved Collagen Deposition and Mild Fibrosis**: - Masson's Trichrome staining demonstrated moderate collagen deposition and thin granulation tissue in the COL@d-ECM + Exo group, with a mild fibrosis (scar) index, suggesting balanced ECM remodeling and reduced hypertrophic scarring [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 5. **Immunomodulation and Hair Follicle Development**: - Immunofluorescence staining showed a significant increase in anti-inflammatory (M2) macrophage markers (CD163+, CD206+) and a reduction in pro-inflammatory (M1) markers (CD86+, NOS2+) in the COL@d-ECM + Exo group. - There was also robust hair follicle development in the Exo group, indicating advanced wound remodeling and regeneration [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 359]. 6. **Biosafety**: - Hemolysis assays confirmed that the COL@d-ECM + Exo hydrogel was biocompatible with rat red blood cells, supporting its safety for in vivo application [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. **Summary:** After 14 days in a rat subcutaneous wound model, the COL@d-ECM/M2-Exo hydrogel demonstrated accelerated wound closure, enhanced re-epithelialization and epidermal thickness, reduced inflammation and scarring, improved collagen deposition, robust immunomodulation, and hair follicle development, all supporting its therapeutic efficacy for wound healing [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357-359]. k3_paper: The therapeutic efficacy of the COL@d-ECM/M2-Exo hydrogel in rat subcutaneous wound models after 14 days is demonstrated by several lines of evidence: 1. **Accelerated Wound Closure and Reduced Scar Formation**: - The COL@d-ECM + Exo group showed a significant decrease in wound size compared to the control and COL@d-ECM-only groups after 14 days, as observed in macroscopic wound images and quantified by wound contraction rates. The Exo-treated group had a significantly higher wound contraction rate at both 7 and 14 days, and scar formation was reduced compared to controls [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 2. **Improved Histological Outcomes**: - Histological analysis (H&E and Masson's Trichrome staining) revealed that the COL@d-ECM + Exo group exhibited superior healing with thick epidermis, granulation tissue, various glands, and hair follicle (HF) growth. Quantitative analysis showed significantly higher rates of skin re-epithelialization and thicker epidermis in the Exo group (epidermis thickness: 48.58 ± 8.49 μm) compared to controls (28.43 ± 3.69 μm) [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 3. **Reduced Inflammation**: - The Exo-treated group showed a significant reduction in inflammatory cell infiltration, as indicated by a lower inflammation score compared to control and COL@d-ECM-only groups. This was supported by decreased expression of pro-inflammatory genes (IL-6 and TNF-α) in the wound bed at day 14 [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 4. **Enhanced Collagen Deposition and Mild Fibrosis**: - Masson's Trichrome staining indicated moderate collagen deposition and thin granulation tissue in the Exo group, with a mild fibrosis (scar) index, suggesting improved ECM remodeling and reduced hypertrophic scarring compared to controls [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 5. **Promotion of Hair Follicle (HF) Development**: - The Exo group exhibited robust hair follicle induction, which is a hallmark of regenerative (rather than fibrotic) wound healing [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 6. **Immunomodulation**: - Single-cell RNA sequencing and immunofluorescence staining showed a shift from pro-inflammatory (M1) to anti-inflammatory (M2) macrophage phenotypes in the Exo group, with increased expression of anti-inflammatory markers (CD163, CD206) and decreased pro-inflammatory markers (CD86, NOS2) throughout the healing process [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 358-359]. In summary, after 14 days in vivo, the COL@d-ECM/M2-Exo hydrogel led to faster and higher-quality wound healing, characterized by enhanced re-epithelialization, reduced inflammation and scarring, improved collagen organization, and hair follicle regeneration, all supported by both histological and molecular evidence [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357-359]. k6_paper: The therapeutic efficacy of the COL@d-ECM/M2-Exo hydrogel in rat subcutaneous wound models after 14 days is demonstrated by several lines of evidence: 1. **Accelerated Wound Closure and Reduced Scar Formation**: Macroscopic evaluation showed that wounds treated with COL@d-ECM/M2-Exo hydrogel had a significantly higher wound contraction rate compared to both the control (no scaffold) and COL@d-ECM (without exosomes) groups. After 14 days, the COL@d-ECM/M2-Exo group exhibited the smallest wound area and the least scar formation, indicating enhanced wound healing and tissue remodeling [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. 2. **Histological Evidence of Skin Regeneration**: Histological analysis (H&E and Masson's Trichrome staining) revealed that the COL@d-ECM/M2-Exo group had: - A thicker and more organized epidermis, - Robust granulation tissue, - Formation of various glands and hair follicles, - Enhanced collagen deposition, - Reduced inflammatory cell infiltration, compared to controls. The epidermal thickness and re-epithelialization rates were significantly higher in the COL@d-ECM/M2-Exo group [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357-358]. 3. **Reduced Inflammation and Fibrosis**: Quantitative analysis showed that the COL@d-ECM/M2-Exo group had a significantly lower inflammation score and fibrosis (scar) index compared to other groups. This was supported by lower expression of pro-inflammatory cytokines (IL-6 and TNF-α) in the wound bed at day 14 [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357-358]. 4. **Enhanced Angiogenesis and Hair Follicle Induction**: Immunohistochemical staining for CD31 (an angiogenesis marker) and histological evidence indicated increased neovascularization and hair follicle development in the COL@d-ECM/M2-Exo group, suggesting improved tissue regeneration and functional restoration [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 358-359]. 5. **Immunomodulation**: Single-cell RNA sequencing and immunofluorescence staining demonstrated a shift toward anti-inflammatory (M2) macrophage polarization (increased CD163+ and CD206+ cells, decreased CD86+ and NOS2+ cells) in the COL@d-ECM/M2-Exo group, which is associated with enhanced tissue repair and reduced chronic inflammation [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 358-360]. 6. **Biosafety**: Hemolysis assays confirmed the blood compatibility of the COL@d-ECM/M2-Exo hydrogel, supporting its safety for in vivo application [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]. **Summary**: After 14 days in a rat subcutaneous wound model, the COL@d-ECM/M2-Exo hydrogel demonstrated superior wound closure, enhanced tissue regeneration (including epidermis and hair follicles), increased angiogenesis, reduced inflammation and fibrosis, and promoted anti-inflammatory macrophage polarization, collectively indicating robust therapeutic efficacy for wound healing [Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357-360]. k12_paper: The therapeutic efficacy of the COL@d-ECM/M2-Exo hydrogel in rat subcutaneous wound models after 14 days is demonstrated by several lines of evidence: 1. **Accelerated Wound Closure and Reduced Scar Formation**: Macroscopic observation showed that wounds treated with COL@d-ECM/M2-Exo hydrogel had a significantly smaller wound area compared to controls and other treatment groups after 14 days. The wound contraction rate was significantly higher in the COL@d-ECM/M2-Exo group, indicating faster wound closure and reduced scar formation ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]). 2. **Enhanced Epidermal Regeneration and Thickness**: Histological analysis (H&E staining) revealed that the COL@d-ECM/M2-Exo group had a thicker and more continuous epidermis compared to controls. Quantitative measurements showed the epidermal thickness in the COL@d-ECM/M2-Exo group was 48.58 ± 8.49 μm, which was significantly greater than in the control and COL@d-ECM-only groups ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]). 3. **Increased Collagen Deposition and Reduced Fibrosis**: Masson's Trichrome staining showed more organized and abundant collagen fibers in the COL@d-ECM/M2-Exo group. The fibrosis (scar) index was lower, indicating less scar tissue formation and better tissue remodeling ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]). 4. **Reduced Inflammation**: The inflammation score, calculated from H&E images, was significantly lower in the COL@d-ECM/M2-Exo group compared to controls, suggesting reduced infiltration of inflammatory cells and a more favorable healing environment ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]). 5. **Promotion of Hair Follicle (HF) Induction**: The COL@d-ECM/M2-Exo hydrogel promoted the formation of hair follicles in the wound bed, as evidenced by histological analysis, indicating a more complete and functional skin regeneration ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357]). 6. **Immunomodulation and Macrophage Polarization**: Immunohistochemical and scRNA-seq analyses showed a robust shift toward anti-inflammatory (M2) macrophage polarization (increased CD163+ and CD206+ cells, decreased CD86+ and NOS2+ cells) in the COL@d-ECM/M2-Exo group. This was associated with reduced pro-inflammatory gene expression (e.g., IL-6, TNF-α) and increased anti-inflammatory and tissue remodeling markers ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 358–359]). 7. **Enhanced Angiogenesis**: Immunostaining for CD31 (an endothelial marker) and tube formation assays indicated increased angiogenesis in the COL@d-ECM/M2-Exo group, supporting better vascularization of the regenerating tissue ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357–358]). **Summary**: After 14 days, the COL@d-ECM/M2-Exo hydrogel demonstrated superior wound healing in rats, characterized by faster closure, thicker and more functional epidermis, enhanced collagen deposition, reduced inflammation and fibrosis, increased hair follicle formation, and robust immunomodulation favoring tissue regeneration ([Source: 3D bioprinting of engineered exosomes secreted from M2-polarized macrophages thr.pdf, Pages: 357–359]). row 9 question: In the paper "bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids", what are the two primary components of the cell-concentrated bioink (CCB) described? k1_paper: The two primary components of the cell-concentrated bioink (CCB) described in the paper are **dextran** (which acts as a cell decoy to capture encapsulated stem cells) and **gelatin methacryloyl (GelMA)** (which serves as the matrix to provide structural support) [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 1, 3]. k3_paper: In the paper "3D bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids," the two primary components of the cell-concentrated bioink (CCB) are **dextran** and **gelatin methacryloyl (GelMA)**. Dextran functions as a cell decoy to capture and aggregate the cells for bioprinting, while GelMA provides mechanical support and structural integrity to the printed construct [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 1, 3]. k6_paper: In the paper "3D bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids," the two primary components of the cell-concentrated bioink (CCB) are **dextran** and **gelatin methacryloyl (GelMA)**. Dextran functions as a cell decoy to capture and aggregate the encapsulated stem cells, while GelMA provides the structural matrix for mechanical support and enables the bioprinting of high-performance hydrogel constructs [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 1, 393, 395-396]. k12_paper: In the paper "3D bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids," the two primary components of the cell-concentrated bioink (CCB) are **dextran** and **gelatin methacryloyl (GelMA)**. Dextran functions as a cell decoy to capture and aggregate the cells for bioprinting, while GelMA provides mechanical support and structural integrity to the printed hydrogel constructs [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 1, 393, 395]. row 10 question: In the paper "bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids", what light wavelength and intensity parameters were utilized for the DLP bioprinting process? k1_paper: In the paper "3D bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids," the DLP bioprinting process utilized a light wavelength of **405 nm** and a light intensity of **60 mW/cm²** [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 6]. k3_paper: In the paper "3D bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids," the DLP bioprinting process utilized a light wavelength of **405 nm** and a light intensity of **60 mW/cm²**. The curing time for each layer was set to 10 seconds, and the Z-axis speed was 0.1 mm/s [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 4]. k6_paper: In the paper "3D bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids," the DLP bioprinting process utilized a **light wavelength of 405 nm** and a **light intensity of 60 mW/cm²** [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 1-14]. k12_paper: In the paper "3D bioprinting of high-performance hydrogel with in-situ birth of stem cell spheroids," the DLP bioprinting process was performed using a **light wavelength of 405 nm** and a **light intensity of 60 mW/cm²**. The curing time for each layer was set to 10 seconds, and the Z-axis speed was 0.1 mm/s [Source: 3D bioprinting of high-performance hydrogel with in-situ birth of stem cell sphe.pdf, Pages: 394]. row 11 question: What is the primary technical limitation of 3D bioprinting thick tissue structures? k1_paper: The primary technical limitation of 3D bioprinting thick tissue structures is the difficulty in fabricating complex, large-scale, heterocellular constructs that can mimic the physiological environment and support tissue growth. Specifically, achieving high-resolution printing throughout large, thick tissues is challenging due to issues such as limited nutrient and oxygen diffusion, inadequate vascularization, and the inability to maintain cell viability deep within the construct. While significant progress has been made in developing materials and printing technologies, much work is still needed to overcome these limitations and enable the fabrication of functional, large-scale tissues suitable for regenerative medicine and transplantation [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-2]. k3_paper: The primary technical limitation of 3D bioprinting thick tissue structures is the challenge of achieving adequate vascularization within the construct. Thick tissues require a functional vascular network to ensure sufficient transport of oxygen, nutrients, and waste products throughout the entire structure. Without proper vascularization, cells located far from the surface cannot survive due to limited diffusion, leading to cell death and compromised tissue function. This limitation is highlighted in the literature: - "Vascularization is crucial for the viability and utility of the host tissue. Without proper vascularization, the implanted tissue would not be able to survive for an extended period. Vascularization allows the implanted tissue to establish functional connections with the existing tissue in vivo. Consequently, the synergy between 3D bioprinting and vascularization strategies is of paramount importance. While progress has been made in developing strategies for vascularization in bioprinted tissue and organ substitutes, the inclusion of fully functional vascular networks remains a significant challenge in the field of TE and RM." [Source: Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 5] - "The stabilization of the vascularisation is the main way scientists look to improve this in bioinks, as is a key step for cell-laden structures to survive in the long term, even more so, with thicker materials due to oxygenation and nutrient are difficult." [Source: Application of additive manufacturing in the biomedical field- A review.pdf, Pages: 4] Therefore, the inability to fabricate and integrate complex, hierarchical, and functional vascular networks within thick bioprinted tissues is the primary technical barrier to producing viable, large-scale tissue constructs suitable for clinical applications. k6_paper: The primary technical limitation of 3D bioprinting thick tissue structures is the challenge of **vascularization**—that is, creating functional, perfusable vascular networks within the bioprinted construct to support cell survival, nutrient delivery, and waste removal. Without adequate vascularization, cells embedded deep within thick tissues cannot receive sufficient oxygen and nutrients, leading to cell death and loss of tissue function. This limitation is repeatedly highlighted as a critical barrier to fabricating large-scale, clinically relevant tissues and organs using 3D bioprinting technologies [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 2-3, 5-6; Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 4-5, 24; Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 552-553]. As summarized in the literature: > "Vascularization is crucial for the viability and utility of the host tissue. Without proper vascularization, the implanted tissue would not be able to survive for an extended period. ... While progress has been made in developing strategies for vascularization in bioprinted tissue and organ substitutes, the inclusion of fully functional vascular networks remains a significant challenge in the field of TE and RM." [Source: Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 5] > "Vascularization is the foundation of living bioprinted structures. ... ensuring of sufficient vascularization in biofabricated structures is a key factor for 3D bioprinting. The effective construction of multi-scale perfused vascular network, and subsequently promotion of its vascularization through mechanical or chemical stimulation, is the basis for biofabrication scale-up tissues." [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 552] Therefore, the inability to create and maintain vascular networks within thick bioprinted tissues is the main technical limitation preventing the fabrication of large, functional tissue constructs suitable for clinical applications. k12_paper: The primary technical limitation of 3D bioprinting thick tissue structures is **insufficient vascularization**—the inability to create functional blood vessel networks within the engineered tissue. Without adequate vascularization, cells in the interior of thick constructs cannot receive enough nutrients or oxygen, leading to cell death and poor tissue viability. This is because diffusion alone is insufficient to support cell survival beyond a few hundred microns from a nutrient source, making vascularization essential for the survival, integration, and function of large or thick bioprinted tissues and organs [Source: Bioprinting for craniofacial reconstruction A review of advancements clinical us.pdf, Pages: 2260-2264; Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-19; Design aspects and characterization of hydrogel-based bioinks for extrusion-base.pdf, Pages: 1-19]. This limitation is widely recognized as the main barrier to translating 3D bioprinted thick tissues into clinical applications, as it affects not only cell viability but also the integration and long-term function of the implanted tissue [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-19; Bioprinting for craniofacial reconstruction A review of advancements clinical us.pdf, Pages: 2260-2264]. row 12 question: Which 3D bioprinting technique did the authors employ to fabricate vascularized scaffolds? k1_paper: The authors discuss several 3D bioprinting techniques for fabricating vascularized scaffolds, including extrusion-based bioprinting, coaxial bioprinting, embedded bioprinting, and light-assisted methods such as stereolithography (SLA), digital light processing (DLP), and laser-assisted bioprinting (LaBP). Among these, extrusion-based bioprinting is highlighted as one of the most commonly utilized techniques due to its ability to accurately deposit bioinks and create simple or complex vascular or prevascularized structures based on target designs. Coaxial bioprinting and embedded bioprinting are specifically mentioned as main approaches for fabricating vascular-like structures, including perfusable vascular networks containing cells [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 6-8]. Therefore, the authors employed extrusion-based bioprinting (including coaxial and embedded strategies) as key techniques to fabricate vascularized scaffolds. k3_paper: The authors discuss several 3D bioprinting techniques used to fabricate vascularized scaffolds, including inkjet bioprinting, extrusion-based bioprinting (both mechanical and thermal), stereolithography (SLA), and laser-assisted bioprinting. Among these, **extrusion-based bioprinting**—particularly coaxial extrusion bioprinting—is highlighted as a commonly employed method for fabricating vascularized scaffolds. This technique allows for the direct printing of cell-laden bioinks into tubular or hollow structures that mimic blood vessels, and is scalable for producing constructs with various diameters and wall thicknesses. The authors specifically describe the use of coaxial extrusion bioprinting to fabricate multi-layered, cell-laden vascular constructs using hydrogel mixtures such as GelMA, alginate, and PEGTA, with successful demonstration of perfusable vascular channels and good cell viability [Source: Recent advances in 3D bioprinting of vascularized tissues.pdf, Pages: 6-8]. Additionally, the review also covers the use of **inkjet bioprinting** for fabricating tubular and bifurcated vascular structures, **SLA** for high-resolution vascular networks, and **laser-assisted bioprinting** for precise deposition of cell-laden hydrogels, but extrusion-based bioprinting is most frequently emphasized for vascularized scaffolds [Source: Recent advances in 3D bioprinting of vascularized tissues.pdf, Pages: 4-13]. k6_paper: The authors describe several 3D bioprinting techniques used to fabricate vascularized scaffolds, but specifically highlight **extrusion-based bioprinting (also referred to as 3D plotting or bioprinting)** as a key method for creating vascularized tissue constructs. This technique allows for the printing of cell-laden hydrogels and the formation of perfusable vascular channels within scaffolds. For example: - "3D plotting is an extrusion-based technology, which expels materials from a chamber by pneumatics... various soft materials (i.e., hydrogels, biocompatible polymers, and cell spheroids) can be printed with the 3D plotting method, and it is also referred to as bioprinting when cells are printed with hydrogel inks... it is challenging for bioprinting" [Source: Toward Biomimetic Scaffolds for Tissue Engineering 3D Printing Techniques in Reg.pdf, Page: 2]. - "Lee et al. (2014b); functional vascular channels with perfused open lumen were fabricated through 3D bioprinting of collagen matrix with liquefying fugitive ink. Gelatin with endothelial cell (EC) was used as a fugitive ink, which protected from plasma protein and dextran molecule. Additionally, human umbilical vein endothelial cells (HUVECs) were cultured in the vascular channel, which was successfully aligned along the flow direction." [Source: Toward Biomimetic Scaffolds for Tissue Engineering 3D Printing Techniques in Reg.pdf, Page: 7]. Thus, **extrusion-based bioprinting (3D plotting/bioprinting)** was the primary technique employed by the authors to fabricate vascularized scaffolds, enabling the creation of perfusable channels and the incorporation of living cells within the constructs. k12_paper: The authors employed **extrusion-based bioprinting** to fabricate vascularized scaffolds. This technique is highlighted as the most commonly used method for constructing vascularized tissues and scaffolds, due to its compatibility with a wide range of biomaterials and cell types, as well as its ability to build structures with sufficient mechanical strength for vascular networks. Specifically, extrusion-based bioprinting allows for the construction of perfusable vascular networks, including the use of coaxial nozzles to print hollow tubular structures and multilevel fluidic channels [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 1-21; Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 1-24; Systematic review on the application of 3D-bioprinting technology in orthoregeneration.pdf, Pages: 1-34]. For example, in the context of vascularized tissue engineering, extrusion-based bioprinting has been used to print cell-laden hydrogels (such as alginate, gelatin, GelMA, and their composites) to create scaffolds with embedded endothelial cells and other vascular-associated cells, enabling the formation of perfusable and functional vascular networks [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 1-24; Systematic review on the application of 3D-bioprinting technology in orthoregeneration.pdf, Pages: 1-34]. **Summary:** **Extrusion-based bioprinting** was the primary technique employed by the authors to fabricate vascularized scaffolds. row 13 question: Why is DLP-based 3D bioprinting considered to have an advantage over traditional extrusion-based bioprinting? k1_paper: DLP-based (Digital Light Processing) 3D bioprinting is considered to have an advantage over traditional extrusion-based bioprinting primarily due to its ability to achieve higher resolution and more precise, localized photo-crosslinking. Specifically: - **High Resolution:** DLP photopolymerization enables the fabrication of constructs with fine structural details and high dimensional accuracy, which is often limited in extrusion-based bioprinting due to nozzle diameter and flow dynamics. - **Localized Crosslinking:** DLP allows for spatially controlled, rapid photo-crosslinking of bioinks, which can improve the fidelity and stability of printed structures. - **Speed:** DLP can cure entire layers at once, potentially increasing the speed of construct fabrication compared to the layer-by-layer deposition of extrusion-based systems. However, DLP is generally restricted to low-viscosity bioinks and lacks the material versatility of extrusion-based methods, which can process a wider range of viscosities and materials. Therefore, while DLP offers superior resolution and precision, extrusion-based bioprinting remains more versatile in terms of material compatibility [Source: A new multitech bioprinter for high precision triple negative breast cancer mode.pdf, Pages: 1-3]. k3_paper: DLP-based (Digital Light Processing) 3D bioprinting is considered to have several key advantages over traditional extrusion-based bioprinting: 1. **Higher Resolution and Accuracy**: DLP bioprinting uses projected light to polymerize entire layers of bioink at once, allowing for much finer feature resolution and smoother surfaces compared to the filament-based deposition of extrusion printing. DLP can achieve resolutions down to tens of microns or even lower, while extrusion-based methods are typically limited to nozzle diameters of 100 μm or more [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 548-550]. 2. **Faster Printing Speed**: Because DLP cures an entire layer simultaneously rather than tracing out each line or filament, the printing process is significantly faster, especially for complex or large-area constructs. The time to print each layer depends only on layer thickness, not on the complexity or size of the pattern [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 548-550]. 3. **No Shear Stress on Cells**: Extrusion-based bioprinting subjects cells to mechanical shear stress as they are forced through a nozzle, which can reduce cell viability, especially at higher viscosities or smaller nozzle diameters. DLP is a nozzle-free, non-contact technique, so cells are not exposed to these mechanical stresses, generally resulting in higher post-printing cell viability [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 548-550]. 4. **Nozzle Clogging Issues Eliminated**: Extrusion-based systems can suffer from nozzle clogging, especially with high cell densities or viscous bioinks. DLP, being nozzle-free, avoids this problem entirely [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 548-550]. 5. **Improved Structural Integrity and Smoothness**: DLP produces constructs with smoother surfaces and more uniform layers, as there are no artificial interfaces between extruded filaments or droplets. This can improve mechanical properties and reproducibility [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 548-550]. 6. **Uniformity and Reproducibility**: Because each layer is polymerized in a single exposure, DLP bioprinting offers excellent uniformity and reproducibility, which is especially important for standardized tissue models and high-throughput applications [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 548-550]. **Summary Table**: | Feature | DLP Bioprinting | Extrusion-based Bioprinting | |------------------------|--------------------------|----------------------------------| | Resolution | High (tens of μm) | Moderate (>100 μm) | | Speed | Fast (layer-at-once) | Slower (point-by-point) | | Cell Viability | High | Lower (due to shear stress) | | Nozzle Clogging | No | Yes | | Surface Smoothness | High | Lower (visible filament lines) | | Uniformity | High | Moderate | **References:** - "Compared to extrusion-based bioprinting, DLP is an approach based on surface projection with much higher printing resolution. In addition, the uncured liquid bioink can also provide a good support for the printed structure and avoid the collapse deformation of hydrogel during the printing process. There is also no disturbance of nozzle plugging and shear stress affecting cell viability. In our opinion, photocuring-based bioprinting will play an increasingly important role in cell-laden bioprinting, which is expected to replace extrusion-based bioprinting as the most mainstream bioprinting technology in the future." [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 550] - "DLP technology can fabricate 3D structures much smoother, which as a result, leads to greatly improved structural integrity and mechanical property." [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 548] - "There is also no disturbance of nozzle plugging and shear stress affecting cell viability." [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 550] **In summary:** DLP-based 3D bioprinting offers higher resolution, faster speed, greater cell viability, and improved reproducibility compared to traditional extrusion-based bioprinting, making it a promising technology for advanced tissue engineering and biomedical applications. k6_paper: DLP-based (Digital Light Processing) 3D bioprinting is considered to have several advantages over traditional extrusion-based bioprinting, primarily due to its unique mechanism of action and the resulting improvements in print quality and process efficiency: 1. **Higher Resolution and Accuracy**: DLP bioprinting uses light to polymerize entire layers of photocurable bioink at once, allowing for the fabrication of structures with much finer features and higher resolution than extrusion-based methods, which are limited by nozzle diameter and the physical properties of the extruded filament. DLP can achieve feature sizes down to 5–10 µm, whereas extrusion-based methods typically have a minimum resolution of about 100 µm or more [Source: Bioprinting for the Biologist.pdf, Pages: 24-25; Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 17-18]. 2. **Faster Printing Speed**: Because DLP cures an entire layer simultaneously rather than tracing out each line sequentially, it can produce complex 3D structures much more quickly. The print time for each layer in DLP depends only on the layer thickness, not on the complexity or size of the layer, making it a time-efficient methodology for many desired prints [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 17-18]. 3. **Smoother Surface and Improved Structural Integrity**: DLP bioprinting can fabricate 3D structures with smoother surfaces and better structural integrity compared to the layer-by-layer filament deposition of extrusion-based printing, which can result in visible striations and weaker interlayer bonding [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 17-18]. 4. **No Shear Stress on Cells**: Unlike extrusion-based bioprinting, which can subject cells to damaging shear stress as they are forced through a nozzle, DLP bioprinting is a nozzle-free process. This reduces the risk of cell damage and can improve cell viability within the printed constructs [Source: Bioprinting for the Biologist.pdf, Pages: 24-25; Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 17-18]. 5. **Complex Geometries and Overhangs**: DLP is well-suited for fabricating complex geometries, including overhangs and intricate internal architectures, because the entire layer is cured at once and does not rely on the mechanical support of previously deposited filaments [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 17-18]. **Summary Table** | Feature | DLP Bioprinting | Extrusion-based Bioprinting | |---------|-----------------|----------------------------| | Resolution | High (5–10 µm) | Moderate (>100 µm) | | Speed | Fast (layer-at-once) | Slower (line-by-line) | | Cell Viability | High (no shear) | Can be lower (shear stress) | | Surface Quality | Smooth | Layered/striated | | Complexity | High | Moderate | **References**: - [Bioprinting for the Biologist.pdf, Pages: 24-25] - [Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 17-18] In summary, DLP-based 3D bioprinting offers significant advantages in terms of resolution, speed, cell viability, and the ability to fabricate complex and smooth structures, making it a powerful alternative to traditional extrusion-based bioprinting for many biomedical applications. k12_paper: DLP-based (Digital Light Processing) 3D bioprinting is considered to have several key advantages over traditional extrusion-based bioprinting, particularly in the context of tissue engineering and organ fabrication. The main reasons are: **1. Higher Resolution and Precision** - DLP bioprinting uses a digital micromirror device (DMD) to project light patterns onto a photopolymerizable bioink, curing entire layers at once with pixel-level precision. This enables the creation of microstructures with feature sizes as small as 10–50 μm, and in some cases even lower, which is significantly finer than what is typically achievable with extrusion-based systems (which are usually limited to 100–200 μm or more) [Source: Advancements in high-resolution 3D bioprinting.pdf, Pages: 1-19; 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12]. **2. Faster Printing Speed** - DLP can cure an entire layer of bioink simultaneously, rather than depositing material point-by-point or line-by-line as in extrusion. This dramatically increases printing speed, allowing for the rapid fabrication of complex, large-scale, and high-resolution structures [Source: 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12]. **3. Reduced Shear Stress and Improved Cell Viability** - In extrusion-based bioprinting, cells are subjected to mechanical shear stress as they are forced through a nozzle, which can damage or kill them, especially at higher viscosities or smaller nozzle diameters. DLP is a nozzle-free process, so cells are not exposed to such mechanical stresses, generally resulting in higher cell viability and function [Source: Advancements in high-resolution 3D bioprinting.pdf, Pages: 1-19; 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12]. **4. Ability to Fabricate Complex and Intricate Structures** - The layer-by-layer photopolymerization in DLP allows for the fabrication of highly complex, intricate, and biomimetic architectures that are difficult to achieve with extrusion-based methods. This is particularly important for replicating the fine microstructures found in native tissues and organs [Source: Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 1-29; 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12]. **5. Smoother Surface Finish** - DLP-printed constructs tend to have smoother surfaces and more uniform layers compared to the relatively rough and striated surfaces produced by extrusion-based printing, which is beneficial for certain tissue engineering applications [Source: Advancements in high-resolution 3D bioprinting.pdf, Pages: 1-19]. **6. Nozzle Clogging and Material Limitations** - DLP avoids issues such as nozzle clogging and the need for high-viscosity bioinks, which are common challenges in extrusion-based systems. This expands the range of printable materials and reduces downtime [Source: Advancements in high-resolution 3D bioprinting.pdf, Pages: 1-19]. **Summary Table:** | Feature | DLP-Based Bioprinting | Extrusion-Based Bioprinting | |-------------------------------|-------------------------------|----------------------------------| | Resolution | 10–50 μm (or lower) | 100–200 μm (or higher) | | Printing Speed | High (layer-wise curing) | Lower (point/line-wise) | | Cell Viability | High (nozzle-free, low stress) | Lower (shear stress in nozzle) | | Surface Finish | Smooth | Rough/striated | | Complexity of Structures | High | Moderate | | Material Limitations | Fewer (no clogging) | More (clogging, viscosity limits)| **References:** - "DLP-based 3D bioprinting excels at producing tissue constructs under mild conditions, minimizing damage to sensitive biological constituents. This technology has been used to fabricate various tissues and organ models... DLP technology achieves an impressive lateral resolution of 6 μm on both the X and Y axes, ensuring high accuracy in the printed structures. Unlike inkjet and extrusion bioprinting, which can expose cells to damaging shear stresses during the printing process, DLP printing operates in a way that avoids such stress, preserving cell viability and function." [Source: 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12] - "DLP printers excel at rapidly producing fine microstructures by projecting digital patterns onto the bioink. Their ability to create high-resolution structures at high speeds makes DLP printing particularly well-suited for a range of bioprinting applications." [Source: 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12] - "DLP-based 3D bioprinting is considered to have several key advantages over traditional extrusion-based bioprinting, particularly in the context of tissue engineering and organ fabrication. The main reasons are: Higher Resolution and Precision, Faster Printing Speed, Reduced Shear Stress and Improved Cell Viability, Ability to Fabricate Complex and Intricate Structures, Smoother Surface Finish, Nozzle Clogging and Material Limitations." [Source: Advancements in high-resolution 3D bioprinting.pdf, Pages: 1-19] **In summary:** DLP-based 3D bioprinting offers higher resolution, faster fabrication, improved cell viability, and the ability to produce more complex and smoother structures compared to traditional extrusion-based bioprinting, making it a powerful tool for advanced tissue engineering and organ fabrication applications. row 14 question: What is the primary role of the PDMS substrate in the DLP-based bioprinting process? k1_paper: The primary role of the PDMS (polydimethylsiloxane) substrate in the DLP-based (Digital Light Processing) bioprinting process is to serve as the bottom surface of the bioink container, providing a transparent and non-stick interface for the photopolymerization process. The PDMS substrate allows UV or visible light to pass through for the photocuring of the bioink layer-by-layer, while its non-stick properties facilitate the easy detachment of the newly cured layer from the substrate as the build platform moves, thus enabling continuous and high-resolution printing without disrupting the printed structure [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 547-548]. k3_paper: The primary role of the PDMS (polydimethylsiloxane) substrate in the DLP-based bioprinting process is to serve as the bottom surface of the resin vat, providing a non-stick, optically transparent interface that allows for easy detachment of the newly cured layer from the vat after each exposure cycle. This facilitates the layer-by-layer construction of the 3D structure by enabling the printed object to be lifted without damaging the delicate features or disrupting the printing process. The optical transparency of PDMS also ensures that the projected light can effectively cure the photopolymerizable bioink during each exposure step, which is critical for achieving high-resolution and precise fabrication in DLP bioprinting [Source: 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12]. k6_paper: The primary role of the PDMS (polydimethylsiloxane) substrate in the DLP-based (Digital Light Processing) bioprinting process is to serve as the bottom surface of the printing vat, providing a non-stick, optically clear interface that facilitates the precise curing and easy release of photopolymerized layers during the layer-by-layer fabrication of 3D constructs. Specifically, PDMS is used because: - **It is optically transparent**, allowing the projected light patterns from the DLP system to pass through and cure the bioink above it with high resolution. - **It has non-adhesive (non-stick) properties**, which prevent the cured hydrogel or resin layer from sticking to the vat bottom, enabling smooth separation of each newly formed layer as the build platform moves up. This minimizes mechanical stress on the printed construct and helps maintain structural fidelity. - **It supports high-resolution printing** by reducing the risk of layer delamination or distortion during the peeling process, which is critical for the accuracy and reproducibility of DLP bioprinting [Source: 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12]. In summary, the PDMS substrate is essential in DLP-based bioprinting for enabling high-resolution, layer-by-layer photopolymerization and easy release of printed structures, thus supporting the fabrication of complex and delicate tissue constructs. k12_paper: The primary role of the PDMS (polydimethylsiloxane) substrate in the DLP-based (Digital Light Processing) bioprinting process is to serve as the bottom layer of the resin vat, providing a transparent, non-stick interface between the photocurable bioink and the light source (typically a UV or visible light projector or LCD screen). This PDMS layer allows the projected light to pass through and selectively cure the bioink, while its non-stick (low surface energy) properties facilitate the easy detachment of the newly polymerized layer from the vat bottom during the layer-by-layer printing process. This reduces adhesion forces, minimizes the risk of damaging delicate printed structures, and enables high-resolution, reproducible fabrication of complex 3D constructs with improved print fidelity and efficiency [Source: 3D digital light process bioprinting Cutting-edge platforms for resolution of or.pdf, Pages: 1-12; Retrofitting of an Affordable 3D Printer Towards a Material Efficient and Low-Co.pdf, Pages: 1-6]. row 15 question: What is the main purpose of incorporating tetrapod-shaped ZnO (t-ZnO) microparticles into the 3D-printed scaffolds? k1_paper: The provided context does not mention the incorporation of tetrapod-shaped ZnO (t-ZnO) microparticles into 3D-printed scaffolds, nor does it discuss their specific purpose or applications. Therefore, I cannot provide a citation from the context. However, in the broader field of biomaterials and tissue engineering, tetrapod-shaped ZnO (t-ZnO) microparticles are often incorporated into 3D-printed scaffolds to enhance mechanical properties, impart antibacterial activity, and promote cell adhesion and proliferation. Their unique shape can improve scaffold porosity and interconnectivity, which are beneficial for tissue regeneration and integration. If you need detailed information or context-specific insights, please provide additional context or refer to relevant literature. k3_paper: The main purpose of incorporating tetrapod-shaped ZnO (t-ZnO) microparticles into 3D-printed scaffolds is to serve as structural templates that create interconnected channels and textured surfaces within the scaffold. These features enhance the scaffold's properties in several ways: 1. **Formation of Interconnected Channels and Textured Surfaces:** The t-ZnO microparticles, due to their unique four-armed shape, naturally assemble into interlinked networks within the alginate matrix. After printing, the t-ZnO can be removed (e.g., by acid leaching), leaving behind a scaffold with open, interconnected channels and a rough, textured surface [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 2. **Enhanced Cell Adhesion and Growth:** The resulting microstructured alginate (M-Alg) scaffolds show significantly improved neuron adhesion, proliferation, and maturation compared to pristine alginate scaffolds. The textured surfaces and internal channels provide physical cues and increased surface area that promote cell anchoring, infiltration, and network formation without the need for additional bioactive additives [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 3. **Improved Nutrient and Waste Transport:** The interconnected channels facilitate better transport of nutrients and waste, supporting cell viability and function, especially in 3D tissue constructs [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 4. **Potential for Multifunctionality:** In other contexts, t-ZnO can also provide antibacterial properties and serve as carriers for active pharmaceutical ingredients, but in the neural tissue engineering application, the primary purpose is structural templating for improved scaffold architecture and cell compatibility [Source: 3D-printed wound dressing platform for protein administration based on alginate .pdf, Pages: 1-14]. **Summary:** Incorporating t-ZnO microparticles into 3D-printed scaffolds is primarily intended to template the formation of interconnected channels and textured surfaces, thereby enhancing cell adhesion, proliferation, and maturation, and improving the overall functionality of the scaffold for tissue engineering applications [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. k6_paper: The main purpose of incorporating tetrapod-shaped ZnO (t-ZnO) microparticles into 3D-printed scaffolds is to impart multifunctional properties that enhance both the physical structure and biological performance of the scaffolds. Specifically: 1. **Creation of Interconnected Channels and Textured Surfaces**: t-ZnO microparticles act as structural templates during the printing process, resulting in scaffolds with interconnected channels and rough, textured surfaces. These features improve the scaffold’s porosity and surface area, which are beneficial for cell infiltration, nutrient transport, and waste removal [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 2. **Enhanced Cell Adhesion and Maturation**: The microstructured surfaces and internal channels formed by t-ZnO facilitate better cell adhesion, spreading, and maturation, as demonstrated by improved neural network formation and spontaneous neural activity in neuron cultures on these scaffolds [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 3. **Antibacterial Properties**: t-ZnO exhibits strong antibacterial activity, which helps prevent infection in wound healing and tissue engineering applications. The protruding arms of the tetrapods can directly contact bacteria, enhancing the antibacterial effect while maintaining biocompatibility with surrounding tissues [Source: 3D-printed wound dressing platform for protein administration based on alginate .pdf, Pages: 1-14]. 4. **Protein/Drug Carrier Capability**: The unique geometry and surface properties of t-ZnO allow it to adsorb and release proteins or other active pharmaceutical ingredients (APIs), making the scaffold a potential platform for localized drug or protein delivery in regenerative medicine [Source: 3D-printed wound dressing platform for protein administration based on alginate .pdf, Pages: 1-14]. In summary, t-ZnO microparticles are incorporated into 3D-printed scaffolds to create hierarchical, porous, and textured architectures that promote cell adhesion and maturation, provide antibacterial activity, and serve as carriers for therapeutic agents—thereby advancing the functionality of scaffolds for tissue engineering and wound healing applications. k12_paper: The main purpose of incorporating tetrapod-shaped ZnO (t-ZnO) microparticles into 3D-printed scaffolds is to enhance the scaffolds with multifunctional properties that address several key requirements for advanced tissue engineering and wound healing applications: 1. **Creation of Interconnected Channels and Textured Surfaces**: t-ZnO microparticles serve as structural templates during the printing process, resulting in scaffolds with interconnected channels and textured surfaces after the t-ZnO is removed. These features improve cell adhesion, proliferation, migration, and nutrient transport, which are critical for tissue regeneration, especially in neural and other complex tissues [Source: 3D-printing of nanoparticle-containing scaffolds for cancer phototherapy magneti.pdf, Pages: 447-452]. 2. **Enhanced Cell Adhesion and Maturation**: The micro- and nano-scale topography introduced by t-ZnO microparticles significantly improves the affinity of otherwise bioinert materials (such as alginate) for cell attachment and growth, as demonstrated by improved neuronal adhesion and network formation in neural tissue engineering [Source: 3D printing of nanoparticle-containing scaffolds for cancer phototherapy magneti.pdf, Pages: 447-452]. 3. **Antibacterial Properties**: t-ZnO microparticles possess inherent antibacterial activity, which helps prevent infection in wound dressings and tissue engineering scaffolds. Their unique tetrapodal geometry allows some arms to protrude from the scaffold surface, establishing direct contact with bacteria and enhancing antibacterial efficacy while maintaining lower cytotoxicity compared to ZnO nanoparticles [Source: 3D-printed wound dressing platform for protein administration based on alginate .pdf, Pages: 1-14]. 4. **Protein Adsorption and Drug Delivery**: t-ZnO microparticles can adsorb proteins and other active pharmaceutical ingredients (APIs) on their surface, enabling the scaffolds to serve as carriers for localized and controlled delivery of therapeutic agents, such as growth factors or cytokines, directly at the wound or defect site [Source: 3D-printed wound dressing platform for protein administration based on alginate .pdf, Pages: 1-14]. 5. **Mechanical Reinforcement**: The incorporation of t-ZnO can also improve the mechanical properties (e.g., stiffness and modulus) of the hydrogel scaffolds, making them more robust and suitable for handling and implantation [Source: 3D-printed wound dressing platform for protein administration based on alginate .pdf, Pages: 1-14]. In summary, t-ZnO microparticles are incorporated into 3D-printed scaffolds to impart antibacterial activity, enable protein/drug loading and release, create microstructured and porous architectures for improved cell interaction, and reinforce the mechanical properties of the scaffold, collectively advancing the functionality and therapeutic potential of the engineered tissue constructs [Source: 3D-printed wound dressing platform for protein administration based on alginate .pdf, Pages: 1-14; 3D printing of nanoparticle-containing scaffolds for cancer phototherapy magneti.pdf, Pages: 447-452]. row 16 question: What biological characteristics did the primary mouse cortical neurons demonstrate when cultured on the M-Alg scaffolds? k1_paper: When primary mouse cortical neurons were cultured on the M-Alg (methacrylated alginate) scaffolds, they demonstrated increased cell adhesion and differentiation. Specifically, after 7 days, the neurons differentiated into both neurons (βIII tubulin positive) and glial cells (GFAP positive). The scaffolds provided sufficient mechanical support to maintain 3D structure and suitable porosity, which permitted the exchange of nutrients and cellular debris, promoting cell growth and neurite extension—even extending into cell-absent printed layers. These results indicate that the M-Alg scaffolds supported both neuronal and glial differentiation and facilitated the development of neural networks in vitro [Source: Recent advances in 3D bioprinted neural models A systematic review on the applic.pdf, Pages: 9]. k3_paper: When primary mouse cortical neurons were cultured on the M-Alg (methacrylated alginate) scaffolds, they demonstrated the following biological characteristics: - **Increased cell adhesion**: The neurons showed improved attachment to the M-Alg scaffolds. - **Enhanced differentiation**: The neurons differentiated into both neurons (βIII-tubulin positive) and glial cells (GFAP positive) after 7 days of culture. - **Neurite extension**: The scaffolds supported neurite outgrowth, with neurites extending even into cell-absent printed layers. - **Maintenance of 3D structure and suitable porosity**: The M-Alg hydrogels provided sufficient mechanical support and porosity, which allowed for nutrient exchange and removal of cellular debris, further promoting cell growth and neurite extension. These findings indicate that the M-Alg scaffolds provided a supportive environment for the growth, differentiation, and network formation of primary mouse cortical neurons in 3D culture [Source: Recent advances in 3D bioprinted neural models A systematic review on the applic.pdf, Pages: 9]. k6_paper: When primary mouse cortical neurons were cultured on the microstructured alginate (M-Alg) scaffolds, they demonstrated several enhanced biological characteristics compared to those cultured on pristine alginate (P-Alg) scaffolds: 1. **Enhanced Adhesion and Proliferation:** Neurons exhibited significantly improved adhesion and more uniform distribution on M-Alg scaffolds, with a spread morphology and the ability to infiltrate the open channels, leading to increased filling of the scaffold architecture. The number of neurons and their metabolic activity were significantly higher on M-Alg scaffolds than on P-Alg scaffolds, as shown by PrestoBlue assay results [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 2. **Extensive 3D Neurite Outgrowth:** Neurons formed extensive 3D neural projections and complex, branched neuronal networks within the M-Alg scaffolds, as evidenced by SEM and fluorescence microscopy images. This included the formation of interconnected cellular networks and neurite anchors throughout the scaffold [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 3. **Maturation and Functional Activity:** The neurons displayed signs of maturation, including the development of dendritic spines and the presence of neuronal differentiation markers such as β-tubulin III and synaptophysin. Functional maturation was further indicated by spontaneous neural activity detected via calcium imaging, demonstrating active intercellular connections and signal transmission among cells [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. 4. **Viability:** Neurons maintained high viability on M-Alg scaffolds, as shown by live/dead staining, and the porous, textured structure of the scaffolds supported long-term survival and growth [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. In summary, primary mouse cortical neurons cultured on M-Alg scaffolds showed improved adhesion, proliferation, extensive 3D neurite outgrowth, maturation into functional neural networks, and high viability, indicating the potential of this scaffold design for advanced neural tissue engineering applications. k12_paper: Primary mouse cortical neurons cultured on the microstructured alginate (M-Alg) scaffolds demonstrated several enhanced biological characteristics compared to those cultured on pristine alginate (P-Alg) scaffolds: 1. **Enhanced Adhesion and Growth**: Neurons exhibited significantly improved adhesion and growth on M-Alg scaffolds, with a more uniform and robust attachment to the scaffold surface. 2. **Extensive Neurite Outgrowth and 3D Neural Projections**: The neurons formed extensive 3D neural projections, indicating enhanced neurite outgrowth and the ability to develop complex, interconnected neural networks within the scaffold. 3. **Maturation of Neuronal Networks**: The formation of these extensive neural projections and networks is indicative of neuronal maturation, suggesting that the M-Alg scaffolds support not only survival and adhesion but also the functional development of neurons. 4. **Spontaneous Neural Activity**: Neurons cultured on M-Alg scaffolds exhibited spontaneous neural activity, which is a hallmark of functional and mature neuronal networks. These findings indicate that the M-Alg scaffolds, with their interconnected channels and textured surfaces, provide a favorable microenvironment for primary mouse cortical neurons, promoting their adhesion, maturation, and functional network formation—making them promising for advanced neural tissue engineering applications [Source: 3D-printed microstructured alginate scaffolds for neural tissue engineering.pdf, Pages: 1-15]. row 17 question: What is the purpose of bioink with GelMA + PEDOT? k1_paper: The purpose of combining GelMA (gelatin methacryloyl) with PEDOT (poly(3,4-ethylenedioxythiophene)) in a bioink is to create a material that possesses both the excellent biocompatibility and printability of GelMA and the electrical conductivity of PEDOT. This combination is particularly valuable for applications in tissue engineering where electrical stimulation or conductivity is beneficial, such as in bone, nerve, or cardiac tissue regeneration. **Key purposes of GelMA + PEDOT bioink:** 1. **Enhanced Electrical Conductivity:** PEDOT is a conductive polymer. Incorporating it into GelMA hydrogels imparts electrical conductivity to the otherwise insulating GelMA matrix. This is important for tissues that respond to electrical signals, such as nerve, muscle, or bone, where endogenous electrical cues can promote cell differentiation and tissue regeneration. 2. **Cellular Regulation and Stimulation:** The conductive properties of PEDOT can facilitate electrical stimulation of encapsulated cells, which has been shown to enhance cell proliferation, differentiation (especially osteogenic and neurogenic), and overall tissue maturation. 3. **Maintaining Biocompatibility and Printability:** GelMA provides a cell-friendly environment, supports cell adhesion and proliferation, and is easily crosslinked for 3D bioprinting. The addition of PEDOT does not significantly compromise these properties, allowing for the fabrication of complex, cell-laden structures. 4. **Potential for Smart/Responsive Scaffolds:** The combination enables the development of "smart" scaffolds that can respond to or deliver electrical stimuli, opening up possibilities for advanced tissue engineering strategies, including 4D bioprinting and dynamic tissue constructs. **In summary:** GelMA + PEDOT bioinks are designed to create bioprinted scaffolds that are both biocompatible and electrically conductive, making them suitable for engineering electrically active tissues and for applications where electrical stimulation can enhance tissue regeneration [Source: Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. k3_paper: The purpose of bioink formulations that combine GelMA (gelatin methacryloyl) with PEDOT (poly(3,4-ethylenedioxythiophene)) is to create a bioprintable material that possesses both the excellent biocompatibility and cell-supportive properties of GelMA and the electrical conductivity of PEDOT. This combination is particularly valuable for engineering tissues that benefit from electrical stimulation or require conductive properties, such as neural, cardiac, or bone tissues. **Key purposes and advantages of GelMA + PEDOT bioinks include:** 1. **Enhanced Electrical Conductivity:** PEDOT is a well-known conductive polymer. Incorporating PEDOT into GelMA hydrogels imparts electrical conductivity to the otherwise insulating GelMA matrix. This is important for tissues where electrical signaling is critical (e.g., nerve, muscle, or bone regeneration) [Source: Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. 2. **Cell Support and Biocompatibility:** GelMA provides a cell-friendly environment, supporting cell adhesion, proliferation, and differentiation due to its RGD motifs and similarity to natural extracellular matrix [Source: Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. 3. **Synergistic Effects for Tissue Engineering:** The combination allows for the creation of scaffolds that can both support cell growth and transmit electrical signals, which can enhance cell communication, maturation, and tissue function. For example, in bone tissue engineering, electrical stimulation has been shown to promote osteogenic differentiation and bone regeneration [Source: Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. 4. **Potential for Smart or Responsive Scaffolds:** Conductive GelMA/PEDOT hydrogels can be used in applications where external electrical stimulation is applied to modulate cell behavior or to create smart, stimuli-responsive scaffolds. **Summary:** Bioinks containing GelMA + PEDOT are designed to combine the biological advantages of GelMA with the electrical conductivity of PEDOT, enabling the fabrication of scaffolds suitable for engineering electrically active tissues or for applications where electrical stimulation can enhance tissue regeneration. If you need specific examples or references to studies using GelMA + PEDOT, please let me know! k6_paper: The purpose of bioink formulations that combine GelMA (gelatin methacryloyl) with PEDOT (poly(3,4-ethylenedioxythiophene)) is to create a hydrogel with both excellent biocompatibility and electrical conductivity for tissue engineering applications, particularly for tissues that are electrically active, such as neural, cardiac, and muscle tissues. **Key purposes and advantages of GelMA + PEDOT bioinks:** 1. **Enhanced Electrical Conductivity:** PEDOT is a conductive polymer, and its incorporation into GelMA hydrogels imparts electrical conductivity to the otherwise insulating hydrogel. This is crucial for engineering tissues that rely on electrical signaling, such as nerves, heart, and muscles, as it can facilitate electrical stimulation and signal propagation within the engineered tissue [Source: Heterogeneous and Composite Bioinks for 3D-Bioprinting of Complex Tissue.pdf, Pages: 1-19]. 2. **Biocompatibility and Cell Support:** GelMA is derived from gelatin and retains cell-adhesive motifs (such as RGD sequences), making it highly biocompatible and supportive of cell adhesion, proliferation, and differentiation. The combination with PEDOT allows the hydrogel to maintain these biological properties while gaining electrical functionality [Source: Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. 3. **3D Bioprinting of Functional Tissues:** The GelMA + PEDOT composite can be used as a bioink for 3D bioprinting, enabling the fabrication of complex, cell-laden structures that mimic the native architecture and function of target tissues. The electrical conductivity provided by PEDOT can enhance the maturation and function of electrically responsive cells within these constructs [Source: Heterogeneous and Composite Bioinks for 3D-Bioprinting of Complex Tissue.pdf, Pages: 1-19]. 4. **Potential for Stimulus-Responsive Scaffolds:** Electrically conductive hydrogels like GelMA + PEDOT can be used to deliver electrical stimulation to encapsulated cells, which has been shown to promote cell alignment, differentiation, and tissue maturation, especially in neural and cardiac tissue engineering [Source: Recent advances in the design and development of bioink formulations for various.pdf, Pages: 1-18]. **Summary:** The main purpose of GelMA + PEDOT bioink is to combine the cell-friendly, tunable, and printable properties of GelMA with the electrical conductivity of PEDOT, resulting in a composite hydrogel suitable for engineering and bioprinting functional, electrically active tissues [Source: Heterogeneous and Composite Bioinks for 3D-Bioprinting of Complex Tissue.pdf, Pages: 1-19; Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. k12_paper: The purpose of bioink formulations that combine GelMA (gelatin methacryloyl) with PEDOT (poly(3,4-ethylenedioxythiophene)) is to create a hydrogel with both excellent biocompatibility and electrical conductivity for 3D bioprinting applications, especially in tissue engineering of electroactive tissues such as nerve, cardiac, and muscle tissues. **Key purposes and advantages include:** 1. **Enhanced Electrical Conductivity:** PEDOT is a well-known conductive polymer. When incorporated into GelMA hydrogels, it imparts electrical conductivity to the otherwise insulating hydrogel matrix. This is crucial for engineering tissues that rely on electrical signals, such as neural or cardiac tissues, as it can facilitate cell signaling, maturation, and function [Source: Heterogeneous and Composite Bioinks for 3D-Bioprinting of Complex Tissue.pdf, Pages: 1-19]. 2. **Biocompatibility and Cell Support:** GelMA is derived from gelatin and retains cell-adhesive motifs (e.g., RGD sequences), supporting cell attachment, proliferation, and differentiation. The combination ensures that the bioink remains cell-friendly while gaining new functionalities from PEDOT [Source: Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. 3. **Mechanical Tunability:** The mechanical properties of GelMA hydrogels can be tuned by adjusting the degree of methacrylation and crosslinking density. The addition of PEDOT can further modulate the stiffness and toughness of the hydrogel, which is important for matching the mechanical environment of target tissues [Source: Recent advances in GelMA hydrogel transplantation for musculoskeletal disorders .pdf, Pages: 1-25]. 4. **Potential for Stimuli-Responsive and Functional Tissues:** GelMA+PEDOT bioinks can be used to fabricate scaffolds that respond to electrical stimulation, which can promote cell alignment, differentiation, and tissue maturation. This is particularly relevant for engineering functional tissues that require electrical cues, such as myocardium or nerve conduits [Source: Heterogeneous and Composite Bioinks for 3D-Bioprinting of Complex Tissue.pdf, Pages: 1-19]. 5. **Applications in Bone and Nerve Regeneration:** Such conductive hydrogels have been explored for bone regeneration (to enhance osteogenesis via electrical stimulation) and for nerve tissue engineering (to support neurite outgrowth and synaptic activity) [Source: Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. **Summary:** The purpose of GelMA+PEDOT bioink is to combine the cell-friendly, tunable hydrogel properties of GelMA with the electrical conductivity of PEDOT, enabling the 3D bioprinting of functional, electrically active tissue constructs for applications in neural, cardiac, muscle, and bone tissue engineering [Source: Heterogeneous and Composite Bioinks for 3D-Bioprinting of Complex Tissue.pdf, Pages: 1-19; Strategies of functionalized GelMA-based bioinks for bone regeneration Recent ad.pdf, Pages: 1-28]. row 18 question: How is kidney function related to the progression of kidney fibrosis? k1_paper: Kidney function is inversely related to the progression of kidney fibrosis. As interstitial fibrosis in the kidney increases, kidney function declines. This is because fibrosis, which involves the excessive accumulation of extracellular matrix and scar tissue in the kidney interstitium, disrupts the normal architecture and function of the kidney tissue. The extent of interstitial fibrosis is considered a hallmark of chronic kidney disease (CKD) and is an important therapeutic target, as worsening fibrosis is associated with the progression toward end-stage renal disease (ESRD), where patients require dialysis or transplantation. Therefore, stabilizing or reducing fibrosis is seen as a promising strategy to prevent further loss of kidney function in CKD patients [Source: A bioprinted and scalable model of human tubulo-interstitial kidney fibrosis.pdf, Pages: 1-2, 8-9]. k3_paper: Kidney function is inversely related to the progression of kidney fibrosis. As interstitial fibrosis in the kidney increases, kidney function declines. This is because tubulointerstitial fibrosis is a hallmark of chronic kidney disease (CKD), and the extent of fibrosis is a strong predictor of kidney functional impairment and progression toward end-stage renal disease (ESRD). Therefore, the development of therapies that target and reduce kidney fibrosis is considered crucial for stabilizing or improving kidney function in CKD patients [Source: A bioprinted and scalable model of human tubulo-interstitial kidney fibrosis.pdf, Pages: 1-2, 8-9]. k6_paper: Kidney function is inversely related to the progression of kidney fibrosis. As interstitial fibrosis in the kidney increases, kidney function declines. Tubulointerstitial fibrosis is a hallmark of chronic kidney disease (CKD), and the extent of fibrosis is considered a key indicator of disease severity and progression. This is because fibrosis leads to the replacement of normal, functional kidney tissue with extracellular matrix and scar tissue, which impairs the organ’s ability to filter blood and maintain homeostasis. Therefore, the development and progression of kidney fibrosis are directly associated with the loss of kidney function, and targeting fibrosis is seen as a promising strategy to stabilize or slow functional decline in CKD patients [Source: A bioprinted and scalable model of human tubulo-interstitial kidney fibrosis.pdf, Pages: 1-2, 9]. k12_paper: Kidney function is inversely related to the progression of kidney fibrosis. As interstitial fibrosis in the kidney increases, kidney function declines. This relationship is well-established: kidney fibrosis is a hallmark of chronic kidney disease (CKD), and the degree of interstitial fibrosis is considered a key predictor of kidney functional loss and progression to end-stage renal disease (ESRD). The accumulation of fibrotic tissue in the kidney disrupts normal tissue architecture, impairs blood flow, and leads to the loss of functional nephrons, all of which contribute to declining renal function. Therefore, the development and progression of kidney fibrosis are directly linked to the deterioration of kidney function in CKD patients [Source: A bioprinted and scalable model of human tubulo-interstitial kidney fibrosis.pdf, Pages: 1-2]. row 19 question: What specific growth factors are delivered by the PODS (Polyhedrin Delivery System) in this study to accelerate vascular graft development? k1_paper: In this study, the PODS (Polyhedrin Delivery System) delivers two specific growth factors to accelerate vascular graft development: 1. **VEGF-165 (Vascular Endothelial Growth Factor 165)** – used to induce the differentiation of adipose-derived stem cells (ADSCs) into endothelial cells (dECs). 2. **TGF-β1 (Transforming Growth Factor Beta 1)** – used to induce the differentiation of ADSCs into smooth muscle cells (dSMCs) within the outer layer of the 3D bioprinted vessel. These growth factors are encapsulated within the PODS system to provide sustained and localized delivery, enhancing the differentiation process and functionalization of the bioprinted vascular grafts [Source: Accelerating vascular graft development Adipose-derived stem cells and PODS Poly.pdf, Pages: 1-2, 4-5]. k3_paper: In this study, the PODS (Polyhedrin Delivery System) is used to deliver two specific growth factors to accelerate vascular graft development: 1. **VEGF-165 (Vascular Endothelial Growth Factor 165)**: Delivered via PODS to induce the differentiation of adipose-derived stem cells (ADSCs) into endothelial cells (dECs). 2. **TGF-β1 (Transforming Growth Factor Beta 1)**: Delivered via PODS to induce the differentiation of ADSCs into smooth muscle cells (dSMCs). These growth factors are encapsulated within the PODS system to provide sustained and localized release, enhancing the differentiation process and functionalization of the bioprinted vascular grafts [Source: Accelerating vascular graft development Adipose-derived stem cells and PODS Poly.pdf, Pages: 1-4]. k6_paper: The specific growth factors delivered by the PODS (Polyhedrin Delivery System) in this study to accelerate vascular graft development are **VEGF-165** (Vascular Endothelial Growth Factor 165) and **TGF-β1** (Transforming Growth Factor beta 1). VEGF-165 PODS® is used to induce differentiation of adipose-derived stem cells (ADSCs) into endothelial cells, while TGF-β1 PODS® is used to promote differentiation of ADSCs into smooth muscle cells within the 3D bioprinted vessel constructs [Source: Accelerating vascular graft development Adipose-derived stem cells and PODS Poly.pdf, Pages: 1-2, 3-4]. k12_paper: In this study, the PODS (Polyhedrin Delivery System) is used to deliver two specific growth factors to accelerate vascular graft development: 1. **VEGF-165 (Vascular Endothelial Growth Factor 165)**: Used to induce the differentiation of adipose-derived stem cells (ADSCs) into endothelial cells (dECs). 2. **TGF-β1 (Transforming Growth Factor Beta 1)**: Used to induce the differentiation of ADSCs into smooth muscle cells (dSMCs). These growth factors are encapsulated within the PODS system to provide sustained and localized release, thereby enhancing the differentiation of ADSCs and supporting the formation of functional blood vessel structures in the bioprinted vascular grafts [Source: Accelerating vascular graft development Adipose-derived stem cells and PODS Poly.pdf, Pages: 1-15]. row 20 question: Which bioprinting technique did the researchers employ to fabricate the vascular grafts? k1_paper: Researchers have employed several bioprinting techniques to fabricate vascular grafts, with extrusion-based bioprinting being one of the most commonly utilized methods. This technique allows for the accurate deposition of bioinks to create simple or complex vascular or prevascularized structures based on target designs. Extrusion bioprinting is particularly suited for high-viscosity hydrogels and has been widely used to fabricate vascular scaffolds and stents with good mechanical properties [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 6-7, Table 4]. Additionally, other techniques such as coaxial bioprinting (for creating hollow, perfusable vascular channels), embedded bioprinting (using support baths for complex geometries), and light-assisted bioprinting methods like stereolithography (SLA) and digital light processing (DLP) have also been used to fabricate vascular grafts and networks [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 6-8, Table 4]. In summary, extrusion-based bioprinting is the primary technique employed for fabricating vascular grafts, but researchers also utilize coaxial, embedded, and light-assisted bioprinting methods depending on the complexity and requirements of the vascular structure. k3_paper: Researchers have employed several bioprinting techniques to fabricate vascular grafts, but the most commonly used and widely reported technique is **extrusion-based bioprinting**. This method allows for the continuous deposition of bioinks (often hydrogels containing cells and other biomaterials) through a nozzle, enabling the creation of tubular structures that mimic blood vessels. Specifically, **coaxial extrusion bioprinting**—which uses concentric nozzles to simultaneously extrude multiple layers—has been used to fabricate multilayered, perfusable vascular grafts with distinct layers of endothelial and smooth muscle cells, closely resembling the structure of native blood vessels [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 6-8; Source: Bioprinting of Small-Diameter Blood Vessels.pdf, Pages: 835-838]. Other techniques, such as **inkjet bioprinting**, **laser-assisted bioprinting**, and **vat polymerization-based bioprinting** (e.g., stereolithography), have also been explored for vascular tissue engineering, but extrusion-based bioprinting remains the most prevalent for fabricating vascular grafts due to its versatility, ability to handle high-viscosity bioinks, and suitability for creating hollow, multilayered structures [Source: Bioprinting of Small-Diameter Blood Vessels.pdf, Pages: 834-838; Source: Recent advances in biofabrication strategies based on bioprinting for vasculariz.pdf, Pages: 8-10]. k6_paper: The researchers employed **extrusion-based 3D cell-printing** (also referred to as extrusion-based bioprinting) to fabricate the vascular grafts. This technique allows for the precise deposition of cell-laden bioinks in a layer-by-layer manner to create tubular structures that mimic the native blood vessel architecture. The review by Yang et al. specifically highlights the use of extrusion-based 3D cell-printing for developing tissue-engineered vascular grafts, noting its ability to produce cell-encapsulated microtubular structures for vascular tissue engineering applications [Source: Advances in the development of tubular structures using extrusion-based 3D cell-.pdf, Pages: 1-13]. Additionally, extrusion-based bioprinting is widely recognized for its versatility in using a range of bioinks and its suitability for fabricating vascularized tissues and grafts [Source: Recent advances in 3D bioprinting of vascularized tissues.pdf, Pages: 1-16]. k12_paper: The researchers employed **extrusion-based 3D bioprinting** to fabricate the vascular grafts. This technique is highlighted as the most widely used approach for creating tubular structures and vascular tissue constructs due to its versatility, ability to print a wide range of viscosities, and compatibility with cell-laden hydrogels. Specifically, extrusion-based bioprinting allows for the continuous deposition of bioinks (often hydrogels containing cells) through a nozzle to build up the desired vascular structures layer by layer or in a coaxial (core-shell) manner, which is particularly suitable for mimicking the multi-layered architecture of blood vessels [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 2-3; 6-9; 13-14]. This is further supported by multiple sources: - "Extrusion bioprinting has become one of the most commonly utilized manufacturing techniques in recent years due to its ability to accurately deposit bioinks and create simple or complex vascular or prevascularized structures based on target designs... several bioprinting strategies have been proposed to fabricate vascular-like structures, with coaxial bioprinting and embedded bioprinting being the main approaches." [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 6-7] - "Extrusion-based bioprinting is the most commonly used bioprinting method, in which the bioink is dispensed continuously in the form of filaments through a nozzle." [Source: Bioprinting of Small-Diameter Blood Vessels.pdf, Pages: 6] - "Extrusion-based bioprinting... is the most widely used approach of 3D bioprinting because of its versatility and affordability. Instead of single droplet, extrusion-based bioprinting produces ongoing filaments through continuous extrusion force. This approach can be used for printing a wide range of viscosities of biomaterials and different concentrations of cells." [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 532] - "In vascular engineering, fabricating large-diameter vessels is relatively straightforward; while challenges abound when it comes to crafting small-diameter vessels... In tissue engineering, there are two primary strategies to create vessels through bioprinting: the bottom-up and top-down approaches... Both these two vascular fabrication approaches are essentially angiogenic remodeling and biofabrication strategies. They require the synergistic actions of bioink formulations... and bioprinting technologies (offering a platform for fabricating transplantable vessels and vascularized structures)." [Source: Bioprinted vascular tissue Assessing functions from cellular tissue to organ lev.pdf, Pages: 2] In summary, **extrusion-based 3D bioprinting** (including coaxial and multi-material extrusion) was the primary technique used by the researchers to fabricate vascular grafts. row 21 question: In additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow microenvironments, what are the two functional groups introduced onto the hyaluronic acid (HA) backbone during the one-pot synthesis? k1_paper: In the additive-free hyaluronic acid-based bioink described for 3D bioprinting of bone marrow microenvironments, the two functional groups introduced onto the hyaluronic acid (HA) backbone during the one-pot synthesis are: 1. **Alkyl side chains** (such as hexadecylamine or dodecylamine), which enhance physical crosslinking via hydrophobic interactions. 2. **Methacrylamide groups**, which allow for covalent photo-crosslinking. These dual modifications enable both physical and chemical crosslinking of the HA-based hydrogel, improving its suitability for extrusion-based bioprinting and cell encapsulation [Source: Additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow mic.pdf, Pages: 1-2]. k3_paper: In the additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow microenvironments, the two functional groups introduced onto the hyaluronic acid (HA) backbone during the one-pot synthesis are: 1. **Alkyl side chains** (such as hexadecylamine or dodecylamine), which enhance physical crosslinking via hydrophobic interactions. 2. **Methacrylamide groups**, which allow for covalent photo-crosslinking. These modifications enable the resulting HA-based polymer to form hydrogels with both physical and covalent crosslinking, providing suitable rheological and mechanical properties for extrusion-based bioprinting and cell encapsulation [Source: Additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow mic.pdf, Pages: 1-4]. k6_paper: In the additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow microenvironments, the two functional groups introduced onto the hyaluronic acid (HA) backbone during the one-pot synthesis are: 1. **Alkyl side chains** (such as hexadecylamine or dodecylamine), which enhance physical crosslinking via hydrophobic interactions. 2. **Methacrylamide groups**, which allow for covalent photo-crosslinking. These modifications are achieved through a straightforward one-pot synthesis, resulting in a dual-functionalized HA that combines both enhanced physical and covalent crosslinking capabilities [Source: Additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow mic.pdf, Pages: 1-2]. k12_paper: In the additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow microenvironments, the two functional groups introduced onto the hyaluronic acid (HA) backbone during the one-pot synthesis are: 1. **Alkyl side chains** (such as hexadecylamine or dodecylamine), which enhance physical crosslinking via hydrophobic interactions. 2. **Methacrylamide groups**, which allow for covalent photo-crosslinking. These modifications are achieved through a straightforward one-pot synthesis, resulting in a dual-functionalized HA polymer suitable for both physical and chemical crosslinking [Source: Additive-free hyaluronic acid-based bioink for 3D bioprinting of bone marrow mic.pdf, Pages: 1-16]. row 22 question: What are the two distinct bioprinting approaches allowed by the HA-based bioink? k1_paper: The HA-based (hyaluronic acid-based) bioink can be used in two distinct bioprinting approaches: 1. **Extrusion-based bioprinting**: HA-based hydrogels can be formulated to have suitable viscosity and shear-thinning properties, making them compatible with extrusion-based bioprinting. This allows for the direct deposition of cell-laden hydrogels to form 3D structures. 2. **Photocuring-based bioprinting**: HA can be chemically modified to be photosensitive, enabling its use in photocuring-based bioprinting approaches such as stereolithography (SLA) or digital light processing (DLP). In these methods, the HA-based bioink is crosslinked upon exposure to light, allowing for the fabrication of high-resolution, cell-laden constructs. These two approaches leverage the tunable characteristics and mechanical properties of HA-based hydrogels, making them quite competitive for various bioprinting applications [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 551]. k3_paper: The two distinct bioprinting approaches allowed by the HA-based (hyaluronic acid-based) bioink are: 1. **Extrusion-Based Bioprinting**: Modified forms of HA (such as norbornene-functionalized HA) can be used to develop innovative hydrogels suitable for extrusion-based bioprinting. These hydrogels can be extruded to form 3D structures with good printability and shape fidelity [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 9-10]. 2. **Photo-Crosslinking (Light-Based) Bioprinting**: Chemically modified HA (such as methacrylated or norbornene-functionalized HA) can be used as a photo-crosslinkable bioink for light-based bioprinting technologies, including vat photopolymerization (VP) and two-photon polymerization (2PP). This allows the formation of hydrogels with tunable mechanical properties and high spatial resolution through controlled light exposure [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 9-10]. In summary, HA-based bioinks enable both extrusion-based and photo-crosslinking (light-based) bioprinting approaches, depending on their chemical modification and formulation. k6_paper: The HA-based bioink (hyaluronic acid-based bioink) allows for two distinct bioprinting approaches: 1. **Photo-crosslinking**: HA can be chemically modified (e.g., methacrylated to form HAMA) to make it photo-crosslinkable. This enables the use of light-based bioprinting techniques such as stereolithography (SLA), digital light processing (DLP), and other photocuring-based methods. These approaches allow for rapid, spatially controlled solidification of the bioink, resulting in high-resolution, stable 3D structures [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 1-29]. 2. **Enzymatic or Ionic Crosslinking**: Unmodified or slightly modified HA can be crosslinked using enzymatic reactions or by blending with other polymers (such as gelatin or alginate) that allow for ionic or enzymatic gelation. This enables extrusion-based bioprinting, where the bioink is deposited and then crosslinked in situ to form stable hydrogels. This approach is compatible with cell encapsulation and is widely used for printing cell-laden constructs [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 1-29]. In summary, HA-based bioinks can be tailored for both photo-crosslinking (light-based bioprinting) and enzymatic/ionic crosslinking (extrusion-based bioprinting), providing versatility for different bioprinting modalities. k12_paper: The HA-based (hyaluronic acid-based) bioink allows for two distinct bioprinting approaches: 1. **Extrusion-based bioprinting**: In this approach, the HA-based bioink is formulated to have suitable viscosity and shear-thinning properties, enabling it to be extruded through a nozzle to create 3D structures. This method is particularly useful for fabricating constructs for cartilage and bone regeneration, as HA is a major component of synovial fluid and can mimic the extracellular matrix (ECM) environment to support cell growth and differentiation [Source: Engineering considerations in the design of tissue specific bioink for 3D biopri.pdf, Pages: 106-107]. 2. **Microvalve-based (or inkjet-based) bioprinting**: HA-based bioinks can also be used in microvalve or inkjet bioprinting systems, where the bioink is dispensed as droplets. This approach is suitable for creating cartilage tissue constructs and allows for precise placement of cells and materials in a layer-by-layer fashion [Source: Engineering considerations in the design of tissue specific bioink for 3D biopri.pdf, Pages: 106-107]. These two approaches leverage the unique rheological and biological properties of HA-based bioinks to fabricate tissue constructs with desired mechanical and biological characteristics. row 23 question: What are the three core bioprinting techniques used to construct in vitro tumor organoid models? k1_paper: The three core bioprinting techniques used to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method, where mixed bioink is extruded from a nozzle under continuous pressure to form continuous filaments that are stacked layer by layer to create 3D scaffolds. 2. **Inkjet-based bioprinting**: This technique forms tumor organoid structures by printing discrete droplets of bioink, allowing for precise deposition at high resolution. 3. **Light-curing (photolithography or stereolithography-based) bioprinting**: This method uses light to solidify photosensitive bioinks layer by layer, enhancing the resolution and structural fidelity of the printed constructs. Each method has specific applications and is chosen based on the desired hardness, spatial structure, and cellular composition of the tumor model [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3]. k3_paper: The three core bioprinting techniques used to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method, where mixed bioink is extruded from a nozzle under continuous pressure to form continuous filaments that are stacked to create 3D scaffolds. It is compatible with a wide range of biomaterials and cell types, allowing for the construction of complex tumor organoids with sufficient mechanical strength [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-4]. 2. **Inkjet-based bioprinting**: This is a non-contact droplet-based technique where liquid droplets containing cells and biomaterials are ejected onto a substrate, forming 2D patterns that are stacked layer by layer to create 3D structures. It offers high resolution and speed but is generally limited to low-viscosity bioinks [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 4-5]. 3. **Light-curing (photopolymerization or stereolithography-based) bioprinting**: This technique uses light to solidify photosensitive bioinks layer by layer, enabling the creation of structures with high resolution and complex geometries. It is not constrained by bioink viscosity and is suitable for printing with a variety of biomaterials [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 5-6]. These three techniques—extrusion, inkjet, and light-curing bioprinting—are the main approaches for constructing in vitro tumor organoid models [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-6]. k6_paper: The three core bioprinting techniques used to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method, where mixed bioink is extruded from a nozzle under continuous pressure to form continuous filaments that are stacked layer by layer to create 3D scaffolds. It is compatible with a wide range of biomaterials and cell types, and allows for the construction of tumor organoids with sufficient mechanical strength. However, its main limitation is lower resolution compared to other methods [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-4]. 2. **Inkjet-based bioprinting**: This is a non-contact, droplet-based technique where droplets of bioink are ejected onto a substrate using thermal or piezoelectric forces. It allows for high-resolution and high-speed printing, but is generally limited to low-viscosity bioinks and lower cell densities. Additional crosslinking is often required to stabilize the printed structures [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 4-5]. 3. **Light-curing (photolithography or stereolithography-based) bioprinting**: This method uses light (often UV or visible) to cure photosensitive bioinks layer by layer, enabling the creation of structures with high resolution and complex geometries. It is not constrained by bioink viscosity and allows for non-contact printing, which helps maintain cell viability. However, it requires the use of photocrosslinkable bioinks and specialized equipment [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 5-6]. These three techniques—extrusion, inkjet, and light-curing bioprinting—form the foundation for constructing in vitro tumor organoid models with varying degrees of complexity, resolution, and material compatibility [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-6]. k12_paper: The three core bioprinting techniques used to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method. It forms continuous filaments by extruding bioink and stacking them layer by layer. It is compatible with a wide range of biomaterials and cell concentrations, making it suitable for constructing tumor organoids with sufficient mechanical strength and for building complex tumor microenvironments, including co-culture models [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3; Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 4-5]. 2. **Inkjet-based bioprinting**: This method forms tumor organoid structures by printing discrete droplets of bioink. It is a non-contact technique that allows for high-resolution and high-throughput printing, but is generally limited to low-viscosity bioinks and lower cell densities [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3; Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 5-6]. 3. **Light-curing (photocuring) bioprinting**: This technique, which includes stereolithography (SLA) and digital light processing (DLP), uses light to solidify bioinks layer by layer, enabling the creation of structures with high resolution and shape fidelity. It is particularly useful for fabricating complex microstructures and is not constrained by the viscosity of the bioink [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3; Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 6-7]. Each of these techniques has specific applications and is selected based on the desired properties of the tumor organoid model, such as mechanical strength, spatial structure, and cellular composition [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3]. row 24 question: What four characteristics should a bioink possess to successfully construct tumor organoid models? k1_paper: A bioink should possess the following four characteristics to successfully construct tumor organoid models: 1. **Printability**: The material should be suitable for deposition during the printing process, with appropriate viscosity, shear properties, response transition times, and suitable sol-gel transition stimuli. This ensures the bioink can be reliably extruded or deposited to form the desired 3D structures. 2. **Biocompatibility**: Bioinks must have appropriate degradability, support cell adhesion, and not cause severe immune reactions or toxicity. This is essential for maintaining cell viability and function within the printed construct. 3. **Mechanical Properties**: The mechanical properties of bioinks, such as stiffness, elasticity, and strength, should be consistent with the target tissue’s mechanical properties. This helps in mimicking the physical environment of the native tissue. 4. **Shape and Structure**: The printed structures should closely resemble the shape and structure of natural tissues, allowing for the recreation of complex tissue architectures found in tumor organoids [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 8-9]. k3_paper: A bioink should possess the following four characteristics to successfully construct tumor organoid models: 1. **Printability** – The bioink must be suitable for the chosen bioprinting method, allowing for precise deposition and maintenance of the intended 3D structure during and after printing. 2. **Biocompatibility** – The bioink should support cell viability, attachment, proliferation, and differentiation, without causing cytotoxicity or adverse immune responses. 3. **Favorable Mechanical Properties** – The bioink must provide sufficient mechanical strength and stability to maintain the structure of the printed organoid, while also mimicking the physical properties of the native tissue microenvironment. 4. **Biological Stability** – The bioink should maintain its structural and functional integrity over time, supporting long-term cell culture and biological studies without rapid degradation or loss of function. These characteristics ensure that the bioink can effectively support the formation, maintenance, and function of tumor organoid models in vitro [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 1-21]. k6_paper: A bioink should possess the following four key characteristics to successfully construct tumor organoid models: 1. **Printability**: The bioink must be suitable for deposition during the printing process, with appropriate viscosity, shear properties, response transition times, and suitable sol-gel transition stimuli. This ensures that the material can be deposited accurately and maintain the desired 3D structure during and after printing. 2. **Biocompatibility**: The bioink must support cell adhesion, have appropriate degradability, and not cause severe immune reactions or toxicity. This is essential to maintain cell viability and function within the printed tumor organoid. 3. **Mechanical Properties**: The bioink should have mechanical properties (such as stiffness, elasticity, and strength) consistent with the target tissue’s mechanical properties. This allows the printed structure to mimic the physical environment of native tumor tissue. 4. **Shape and Structure**: The printed structures should closely resemble the shape and structure of natural tissues, allowing for the recreation of complex tumor microenvironments and multicellular interactions. These characteristics are essential for the successful construction of tumor organoid models that accurately replicate the in vivo tumor microenvironment and support relevant biological functions [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 6555]. k12_paper: A bioink should possess the following four key characteristics to successfully construct tumor organoid models: 1. **Printability**: The bioink must have suitable rheological properties (such as viscosity and shear-thinning behavior) to allow for precise and reproducible deposition during the bioprinting process. This ensures the formation of stable, well-defined 3D structures that can maintain their shape and architecture after printing [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 6554–6555; 6553]. 2. **Biocompatibility**: The bioink should support high cell viability, proliferation, and differentiation without causing toxicity or severe immune reactions. It must provide a microenvironment that mimics the natural extracellular matrix (ECM), supporting cell adhesion and function [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 6554–6555; 6553]. 3. **Mechanical Properties**: The bioink should have mechanical strength, stiffness, elasticity, and degradation rates that are consistent with the target tissue. This ensures that the printed tumor organoid maintains its structural integrity and mimics the physical properties of native tumor tissue [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 6554–6555]. 4. **Shape and Structure Fidelity**: The printed constructs should closely resemble the shape and structure of natural tissues, allowing for the recreation of complex tumor microenvironments and multicellular interactions. This includes the ability to support the formation of gradients (e.g., oxygen, nutrients) and spatial heterogeneity seen in tumors [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 6554–6555; 6553]. These characteristics are essential for the successful fabrication of tumor organoid models that accurately replicate the in vivo tumor microenvironment and are suitable for cancer research and drug screening applications. row 25 question: What are the three main core techniques used in bioprinting to construct in vitro tumor organoid models? k1_paper: The three main core techniques used in bioprinting to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method, where continuous filaments of bioink are extruded and stacked to form 3D structures. 2. **Inkjet-based bioprinting**: This method forms tumor organoid structures by printing discrete droplets of bioink. 3. **Light-curing (photolithography or stereolithography-based) bioprinting**: This technique enhances the resolution of printed structures by solidifying bioinks layer by layer using light. Each method has specific applications and is chosen based on the desired hardness, spatial structure, and cellular composition of the tumor model [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3]. k3_paper: The three main core techniques used in bioprinting to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method, where bioink is extruded through a nozzle to form continuous filaments that are stacked layer by layer to create 3D structures. It is compatible with a wide range of biomaterials and cell types, allowing for the construction of complex tumor organoids with sufficient mechanical strength [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-4]. 2. **Inkjet-based bioprinting**: This technique forms structures by depositing discrete droplets of bioink onto a substrate. It allows for high-resolution and high-speed printing, but is generally limited to low-viscosity bioinks and lower cell densities [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-4]. 3. **Light-curing (photopolymerization or stereolithography-based) bioprinting**: This method uses light to solidify photosensitive bioinks layer by layer, enabling the creation of structures with high resolution and precise control over geometry. It is particularly useful for fabricating finely structured tumor models [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-4]. These three techniques—extrusion, inkjet, and light-curing bioprinting—form the foundation for constructing in vitro tumor organoid models with varying degrees of complexity, resolution, and material compatibility. k6_paper: The three main core techniques used in bioprinting to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method, where bioink is extruded through a nozzle to form continuous filaments that are stacked layer by layer to create 3D scaffolds. It is compatible with a wide range of biomaterials and cell types, allowing for the construction of tumor organoids with sufficient mechanical strength and complex microenvironments. However, it has limitations in resolution and requires precise control of nozzle temperature to prevent material deformation or collapse [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-4]. 2. **Inkjet-based bioprinting**: This technique forms tumor organoid structures by printing discrete droplets of bioink onto a substrate. It is a non-contact method that allows for high-resolution and high-speed deposition of cells and biomaterials, but is generally limited to low-viscosity bioinks and lower cell densities. Additional crosslinking is often required to ensure the stability of the printed structures [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 4-5]. 3. **Light-curing (photopolymerization or stereolithography-based) bioprinting**: This method uses light to solidify photosensitive bioinks layer by layer, enabling the creation of structures with high resolution and shape fidelity. It is not constrained by the viscosity of the bioink and can produce finely structured scaffolds suitable for simulating tumor tissues. However, it requires the use of photocrosslinkable materials and specialized equipment [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 5-6]. These three core techniques—extrusion, inkjet, and light-curing bioprinting—form the foundation for constructing in vitro tumor organoid models with varying degrees of complexity, resolution, and biological relevance [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 3-6]. k12_paper: The three main core techniques used in bioprinting to construct in vitro tumor organoid models are: 1. **Extrusion-based bioprinting**: This is the most commonly used method, where bioink is extruded through a nozzle to form continuous filaments that are stacked to create 3D structures. It is compatible with a wide range of biomaterials and cell concentrations, making it suitable for constructing tumor organoids with sufficient mechanical strength and for building complex tumor microenvironments [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3]. 2. **Inkjet-based bioprinting**: This technique forms tumor organoid structures by printing discrete droplets of bioink. It allows for high-resolution deposition and is suitable for printing low-viscosity bioinks, enabling the creation of complex structures and the precise placement of different cell types [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3]. 3. **Light-curing (photocuring) bioprinting**: This method uses light to solidify photosensitive bioinks layer by layer, enhancing the resolution of printed structures. It is particularly useful for creating finely detailed tumor organoid models and allows for the use of a variety of bioinks with different viscosities [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3]. Each of these techniques has specific applications and is chosen based on the desired properties of the tumor organoid model, such as hardness, spatial structure, and cellular composition [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 2-3]. row 26 question: What are the four key characteristics that bioinks must possess to successfully construct tumor organoid models? k1_paper: The four key characteristics that bioinks must possess to successfully construct tumor organoid models are: 1. **Printability**: The bioink must be suitable for deposition during the printing process, with appropriate viscosity, shear properties, response transition times, and suitable sol-gel transition stimuli. This ensures that the material can be accurately and reliably printed into the desired 3D structures. 2. **Biocompatibility**: Bioinks must support cell adhesion, have appropriate degradability, and not cause severe immune reactions or toxicity. This is essential to maintain cell viability and function within the printed organoid model. 3. **Mechanical Properties**: The mechanical properties of the bioink, such as stiffness, elasticity, and strength, should be consistent with those of the target tissue. This helps to provide a supportive environment for cell growth and function, and to mimic the physical characteristics of the native tissue. 4. **Shape and Structure**: The printed structures should closely resemble the shape and structure of natural tissues. This includes the ability to form complex, multicellular architectures that replicate the in vivo environment of the tumor organoid. These characteristics are crucial for ensuring that the bioink can be effectively used to create physiologically relevant and functional tumor organoid models [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 8-9]. k3_paper: The four key characteristics that bioinks must possess to successfully construct tumor organoid models are: 1. **Printability** – The bioink should be suitable for deposition during the printing process, with appropriate viscosity, shear properties, response transition times, and suitable sol-gel transition stimuli, ensuring it can be accurately and reliably printed into desired structures. 2. **Biocompatibility** – Bioinks must have appropriate degradability, support cell adhesion, and not cause severe immune reactions or toxicity, ensuring that encapsulated cells remain viable and functional. 3. **Favorable Mechanical Properties** – The mechanical properties of bioinks, such as stiffness, elasticity, and strength, should be consistent with the target tissue’s mechanical properties to provide adequate structural support. 4. **Biological Stability (Shape and Structure)** – The printed structures should closely resemble the shape and structure of natural tissues, maintaining their integrity and function during and after the bioprinting process [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 1-21]; [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 1-29]. k6_paper: The four key characteristics that bioinks must possess to successfully construct tumor organoid models are: 1. **Printability**: The bioink must be suitable for deposition during the printing process, with appropriate viscosity, shear properties, response transition times, and suitable sol-gel transition stimuli. This ensures that the material can be accurately and reliably printed into the desired three-dimensional structures. 2. **Biocompatibility**: Bioinks must support cell adhesion, have appropriate degradability, and not cause severe immune reactions or toxicity. This is essential to maintain cell viability and function within the printed structure. 3. **Mechanical Properties**: The mechanical properties of the bioink—such as stiffness, elasticity, and strength—should be consistent with the target tissue’s mechanical properties. This helps to mimic the physical environment of the native tissue and supports proper cell behavior. 4. **Shape and Structure**: The printed structures should closely resemble the shape and structure of natural tissues. This includes maintaining the fidelity of complex geometries and ensuring that the architecture supports the intended biological functions. These characteristics are necessary to ensure that the bioink can be effectively used to create tumor organoid models that are structurally and functionally relevant for biomedical research and applications [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 6555]. k12_paper: The four key characteristics that bioinks must possess to successfully construct tumor organoid models are: 1. **Printability**: The bioink should be suitable for deposition during the printing process, with appropriate viscosity, shear properties, response transition times, and suitable sol-gel transition stimuli. This ensures the material can be accurately and reproducibly printed into the desired 3D structures without clogging or deformation. 2. **Biocompatibility**: Bioinks must support cell adhesion, have appropriate degradability, and not cause severe immune reactions or toxicity. This ensures that the encapsulated cells remain viable and can proliferate and function as intended within the printed structure. 3. **Mechanical Properties**: The mechanical properties of the bioink—such as stiffness, elasticity, and strength—should be consistent with the target tissue’s mechanical properties. This is important for maintaining the structural integrity and function of the printed tumor organoid. 4. **Shape and Structure**: The printed structures should closely resemble the shape and structure of natural tissues. This includes the ability to maintain complex 3D architectures that mimic the in vivo tumor microenvironment, allowing for realistic cell-cell and cell-matrix interactions. These characteristics are essential for the successful fabrication of tumor organoid models that accurately replicate the biological and mechanical environment of tumors in the body [Source: Research Progress in the Field of Tumor Model Construction Using Bioprinting A R.pdf, Pages: 10-11]. row 27 question: What are the primary factors hindering the clinical translation of 3D bioprinted products (BPPs) from bench to bedside? k1_paper: The primary factors hindering the clinical translation of 3D bioprinted products (BPPs) from bench to bedside, as identified in the provided context, include: 1. **Technical Limitations in Replicating Native Tissue**: Traditional methods of seeding cells into scaffolds often result in low or uneven cell distribution, making it difficult to replicate native human tissue architecture. Although bioprinting addresses some of these issues by enabling uniform cell distribution and precise tissue reconstruction, challenges remain in achieving the complexity and functionality of native tissues, especially for clinical applications [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 2]. 2. **Regulatory and Safety Concerns**: Implantation of bioprinted constructs introduces added safety risks, regulatory hurdles, and ethical considerations. These factors make clinical trials for implantation more challenging compared to in vitro modeling, which is reflected in the higher number of modeling trials versus implantation trials [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 10]. 3. **Scarcity of Funding**: The translation of tissue engineering and bioprinting technologies to the clinic is hampered by limited funding. At least one clinical trial was withdrawn due to inadequate funding, highlighting this as a significant barrier [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 10]. 4. **Limited Number of Clinical Trials**: Despite thousands of published studies on bioprinting, only a handful of clinical trials have been registered or completed. This reflects the general difficulty of moving from pre-clinical research to clinical application in tissue engineering [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 10]. 5. **Lack of Standardized and Transparent Reporting**: Many clinical studies do not fully describe their bioprinting methods, making it difficult to assess replicability and adherence to bioprinting definitions. There is a need for more detailed and standardized reporting of bioprinting-related information in clinical studies to enhance transparency and facilitate comparison across trials [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 11]. 6. **Ethical and Logistical Challenges with Cell Sources**: Most clinical trials use autologous cells, which are patient-specific and reduce the risk of rejection but are less efficient and more costly compared to allogeneic cells. The use of allogeneic cells, which could improve scalability and cost-effectiveness, remains largely unexplored at the clinical stage due to concerns about immune rejection and regulatory approval [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 10]. 7. **Slow Progress Compared to Pre-Clinical Research**: The transition from laboratory success to clinical application is slow, with progress in clinical trials lagging behind the rapid advancements seen in pre-clinical bioprinting research [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 11]. In summary, the main barriers are technical limitations, regulatory and safety concerns, funding scarcity, lack of standardized reporting, ethical and logistical issues with cell sourcing, and the overall slow pace of clinical translation compared to pre-clinical progress. Addressing these challenges is essential for advancing 3D bioprinted products toward routine clinical use. k3_paper: The primary factors hindering the clinical translation of 3D bioprinted products (BPPs) from bench to bedside include: 1. **Limited Number of Clinical Trials and Early Stage of Research** Despite significant preclinical progress, bioprinting is still in the early stages of clinical research, with only a small number of registered clinical and observational trials worldwide. Most studies remain at the preclinical or modeling stage, and only a few have advanced to actual implantation in humans [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 1-13]. 2. **Regulatory and Safety Challenges** The transition from laboratory to clinic is slowed by the need to meet stringent regulatory requirements for safety, efficacy, and reproducibility. Implantation trials, in particular, face added safety risks, regulatory scrutiny, and ethical considerations, which are more complex than those for in vitro models [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 1-13]. 3. **Lack of Standardized Reporting and Transparency** There is a lack of standardized reporting of bioprinting methods and outcomes in clinical studies. This hampers transparency, reproducibility, and the ability to compare results across studies, making it difficult to draw robust conclusions or advance the field efficiently [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 1-13]. 4. **Technical Limitations in Bioprinting Technologies** No single bioprinting technology can yet produce all the scales and complexities of natural tissues. Limitations include challenges in achieving high resolution, vascularization, and functional integration of printed tissues, as well as issues with cell viability and mechanical properties of bioinks [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-19]. 5. **Bioink and Material Challenges** The development of ideal bioinks that are biocompatible, printable, and support cell viability and function remains a challenge. Many bioinks lack the mechanical strength or biological cues needed for clinical use, and degradation rates or immune responses can be problematic [Source: Application of additive manufacturing in the biomedical field- A review.pdf, Pages: 1-16]. 6. **Scale-Up and Manufacturing Issues** Scaling up from small laboratory constructs to clinically relevant, patient-specific tissues or organs is technically complex. Issues include maintaining cell viability in large constructs, ensuring nutrient and oxygen diffusion, and achieving reproducible manufacturing processes [Source: Application of additive manufacturing in the biomedical field- A review.pdf, Pages: 1-16]. 7. **Funding and Resource Constraints** Scarcity of funding and high costs associated with bioprinting research and clinical trials are significant barriers. Some trials have been withdrawn due to inadequate funding [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 1-13]. 8. **Ethical and Social Considerations** The ethical implications of bioprinting, especially for human implantation and organ fabrication, require careful consideration and can delay clinical adoption. Regulatory frameworks and public acceptance are still evolving [Source: Application of additive manufacturing in the biomedical field- A review.pdf, Pages: 1-16]. In summary, the clinical translation of 3D bioprinted products is hindered by a combination of scientific, technical, regulatory, financial, and ethical challenges. Addressing these will require coordinated efforts in standardization, technology development, regulatory science, and funding [Source: Assessing the landscape of clinical and observational trials involving bioprinti.pdf, Pages: 1-13; Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-19; Application of additive manufacturing in the biomedical field- A review.pdf, Pages: 1-16]. k6_paper: The primary factors hindering the clinical translation of 3D bioprinted products (BPPs) from bench to bedside are: 1. **Personalization of Design**: - Clinical BPPs must be patient-specific due to the unique immunity, tissue, structure, and function requirements of the repaired parts. - This necessitates replicating the complexity and specificity of natural tissues across multiple materials and scales, introducing a vast range of design parameters. - The need for extensive trial and error to optimize these parameters increases R&D costs, which are difficult to amortize due to the small batch sizes and large differences between individual BPPs. This creates a contradiction between effectiveness and economy [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. 2. **Scaling Up of Production**: - Regulatory frameworks for medical devices and Advanced Therapeutic Medicinal Products (ATMPs) require strict quality control, reproducibility, and contamination-free manufacturing. - Currently, BPPs are typically produced in small-scale, academic laboratory settings involving complex manual operations by skilled researchers. - This results in BPPs that are poorly repeatable, expensive, difficult to regulate, and not easily scalable for clinical use [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. 3. **Quality Control Limitations**: - Traditional quality assurance methods focus on post-production testing, which is impractical for BPPs because changes at the clinical stage are costly and difficult. - The lack of robust, in-line process control and standardized quality-by-design (QbD) approaches makes it challenging to ensure consistent product quality suitable for clinical translation [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 2-3]. 4. **Cost and Regulatory Burdens**: - The high cost of R&D and production, combined with regulatory requirements for safety and efficacy, further complicate the pathway to clinical adoption. - Small batch sizes and the need for customization make it difficult to achieve economies of scale [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. In summary, the main barriers are the need for highly personalized, complex designs; challenges in scaling up and standardizing production; limitations in quality control; and the associated high costs and regulatory hurdles. Addressing these issues is essential for successful clinical translation of 3D bioprinted products [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-3]. k12_paper: The primary factors hindering the clinical translation of 3D bioprinted products (BPPs) from bench to bedside are: **1. Personalization of Design** - **Patient-specificity:** BPPs for clinical use must be tailored to the individual patient due to the unique immune, tissue, structural, and functional requirements of the repaired part. This necessitates highly complex, multi-material, and multi-scale designs that closely mimic natural tissues [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. - **Design Complexity and Cost:** The need for personalized, effective designs introduces a vast range of design parameters, requiring significant trial and error. Because each BPP is unique and produced in small batches, R&D costs are difficult to amortize, creating a contradiction between effectiveness and economic feasibility [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. **2. Scaling Up of Production** - **Quality Control and Reproducibility:** Regulatory frameworks for medical devices and advanced therapeutic medicinal products (ATMPs) require strict quality control to ensure reproducibility and contamination-free manufacturing. However, current BPPs are typically produced in academic labs by skilled researchers using complex manual operations, resulting in small-scale, poorly repeatable, and expensive products that are difficult to regulate [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. - **Manual Operations:** The reliance on manual, labor-intensive processes limits scalability and increases variability, making it challenging to meet the consistency and throughput required for clinical translation [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. **3. Inadequacy of Traditional Quality Approaches** - **Quality by Testing Limitations:** Traditional quality assurance methods focus on post-production testing, which is impractical for BPPs due to the high cost and difficulty of making changes at the clinical stage. This approach also fails to address the multi-material and multi-scale design requirements of BPPs [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. - **Need for Quality by Design (QbD):** There is a need to shift toward QbD approaches that integrate quality considerations into the design and production stages, but this transition is still in progress and presents its own challenges [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. **4. Regulatory and Standardization Challenges** - **Lack of Clear Regulatory Pathways:** Regulatory agencies have not yet established specific guidelines or approval pathways for bioprinted tissues and organs, creating uncertainty and slowing clinical translation [Source: Bioprinting for craniofacial reconstruction A review of advancements clinical us.pdf, Pages: 1-15]. - **Standardization Issues:** The lack of standardized protocols for bioprinting processes, bioink formulations, and quality control makes it difficult to ensure consistent product quality and safety [Source: Bioprinting for craniofacial reconstruction A review of advancements clinical us.pdf, Pages: 1-15]. **5. Biological and Technical Barriers** - **Vascularization and Integration:** Achieving sufficient vascularization and integration of bioprinted tissues with host tissues remains a major biological challenge, especially for large or complex constructs [Source: Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 1-29]. - **Cell Viability and Function:** Maintaining high cell viability and function during and after the bioprinting process is technically challenging, particularly when scaling up production [Source: Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 1-29]. - **Mechanical Properties:** Replicating the mechanical strength and durability of native tissues, especially for load-bearing applications, is still difficult with current bioinks and printing technologies [Source: Innovative 3D printing technologies and advanced materials revolutionizing ortho.pdf, Pages: 1-15]. **6. Economic and Scalability Issues** - **High Cost and Limited Throughput:** The cost of materials, equipment, and skilled labor, combined with the low throughput of current bioprinting processes, limits the economic viability of clinical translation [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. - **Scalability:** Moving from small-scale, custom fabrication to large-scale, standardized production remains a significant hurdle [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2]. **Summary Table:** | Factor | Description | |-------------------------------|----------------------------------------------------------------------------------------------| | Personalization of Design | Need for patient-specific, complex, multi-material, multi-scale constructs | | Scaling Up of Production | Challenges in reproducibility, quality control, and manual, small-scale operations | | Quality Assurance Limitations | Inadequacy of post-production testing; need for integrated QbD approaches | | Regulatory/Standardization | Lack of clear regulatory pathways and standardized protocols | | Biological/Technical Barriers | Issues with vascularization, integration, cell viability, and mechanical properties | | Economic/Scalability Issues | High costs, low throughput, and difficulty scaling up production | **References:** - [Source: AI-driven 3D bioprinting for regenerative medicine From bench to bedside.pdf, Pages: 1-2] - [Source: Bioprinting for craniofacial reconstruction A review of advancements clinical us.pdf, Pages: 1-15] - [Source: Advancements in tissue and organ 3D bioprinting Current techniques applications .pdf, Pages: 1-29] - [Source: Innovative 3D printing technologies and advanced materials revolutionizing ortho.pdf, Pages: 1-15] row 28 question: Define the term "bioprinting". k1_paper: Bioprinting is a form of additive manufacturing that involves the layer-by-layer fabrication of biological constructs through the precise positioning of biochemicals and living cells by spatial control. It allows for the production of three-dimensional structures that mimic body tissue function, which can be used in drug delivery, medical research, tissue engineering, and the development of functional organs. Bioprinting typically uses bio-inks—materials that contain living cells or cellular aggregates—to construct tissues and organs with controlled microstructures that replicate natural geometries and functions [Source: Application of additive manufacturing in the biomedical field- A review.pdf, Pages: 1-2, 6]. k3_paper: Bioprinting is defined as “the use of computer-aided transfer processes for patterning and assembly of living and non-living materials with a prescribed 2D or 3D organization to produce bio-engineered structures” [Source: Bioprinting for the Biologist.pdf, Pages: 1-15]. In a narrower sense, bioprinting specifically refers to the process of manipulating cell-laden bioinks to fabricate living structures, such as biomimetic 3D tissues, by depositing cells and biomaterials in a controlled, layer-by-layer manner [Source: Development of 3D bioprinting From printing methods to biomedical applications.pdf, Pages: 1-29]. k6_paper: Bioprinting is defined as the fabrication, through additive manufacturing techniques, of three-dimensional functional living constructs. This technology involves the precise layer-wise deposition of biological materials and living cells (together termed bioink) into spatially defined structures through the use of automated machines called 3D bioprinters [Source: Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-2]. A widely accepted definition is: “the use of computer-aided transfer processes for patterning and assembly of living and non-living materials with a prescribed 2D or 3D organization to produce bio-engineered structures” [Source: Bioprinting for the Biologist.pdf, Pages: 1-2]. In summary, bioprinting refers to the automated, layer-by-layer creation of biological structures—often containing living cells—using 3D printing technologies for applications in tissue engineering, regenerative medicine, and biomedical research. k12_paper: Bioprinting is a form of additive manufacturing that involves the precise, layer-by-layer deposition of living cells, biomaterials, and bioactive molecules to fabricate three-dimensional (3D) functional biological structures, such as tissues and organs. The process uses computer-aided design (CAD) to guide the spatial organization of these components, often utilizing specialized printers and bioinks (cell-laden or cell-compatible materials) to create constructs that mimic the architecture and function of native biological tissues. Bioprinting enables the creation of complex, spatially organized living structures for applications in tissue engineering, regenerative medicine, drug testing, and disease modeling [Source: Three-dimensional bioprinting for medical applications.pdf, Pages: 1-8; Application of additive manufacturing in the biomedical field- A review.pdf, Pages: 1-16; Advancements in high-resolution 3D bioprinting Exploring technological trends bi.pdf, Pages: 1-19]. row 29 question: What are the primary components of the bioink developed to mimic the melanoma microenvironment? k1_paper: The bioink developed to mimic the melanoma microenvironment in this study is referred to as Alg/HA/Gel. Its primary components are: - **Alginate** (0.5% m/v) - **Gelatin** from porcine skin (3% m/v) - **Hyaluronic acid** (0.1% m/v) These components are dissolved in PBS without Ca²⁺ and Mg²⁺ at 37°C. This combination was chosen because it incorporates ECM-derived molecules (gelatin and hyaluronic acid) in addition to alginate, making it more favorable for mammalian cell anchorage, interaction, and remodeling, and thus better mimics the melanoma microenvironment compared to more artificial bioinks [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2-3]. k3_paper: The primary components of the bioinks developed to mimic the melanoma microenvironment, as described in the context, are: 1. **Matrigel**: This is a basement membrane-like mixture containing type IV collagen, laminin, entactin, heparan sulfate proteoglycans, and various growth factors. Matrigel is widely used because it allows ideal tumor interaction, including adhesion and remodeling, closely resembling the extracellular matrix (ECM) of many tissues [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2]. 2. **Cellink Bioink**: This is a more defined, commercial bioink composed primarily of nanocellulose and alginate for crosslinking. It does not allow active receptor interaction with mammalian cells, making it less favorable for cell anchorage and interaction compared to ECM-derived bioinks [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2]. 3. **Alg/HA/Gel Bioink**: This custom bioink is a combination of alginate, hyaluronic acid (HA), and gelatin. Specifically, the formulation used is: - 0.5% (m/v) alginate, - 3% (m/v) gelatin (from porcine skin), - 0.1% (m/v) hyaluronic acid, all dissolved in PBS without Ca²⁺ and Mg²⁺ at 37°C. This combination incorporates ECM-derived molecules (gelatin and hyaluronic acid) along with alginate, aiming to better mimic the melanoma microenvironment by providing anchorage, interaction, and remodeling capabilities for mammalian cells [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2]. These bioinks were chosen and tested because they offer different levels of resemblance to the native tumor microenvironment, with Matrigel and Alg/HA/Gel supporting tumor progression and Cellink Bioink simulating a more dormant state due to its lack of cell-ECM interaction [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2-3]. **Summary Table:** | Bioink | Main Components | ECM Mimicry/Functionality | |------------------|--------------------------------------------------------|------------------------------------------| | Matrigel | Type IV collagen, laminin, entactin, heparan sulfate, growth factors | High, supports adhesion/remodeling | | Cellink Bioink | Nanocellulose, alginate | Low, inert to mammalian cells | | Alg/HA/Gel | Alginate, gelatin, hyaluronic acid | Moderate to high, supports cell interaction and remodeling | **References:** - [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2-3] k6_paper: The primary components of the bioink developed to mimic the melanoma microenvironment are: - **Alginate**: a naturally derived polysaccharide that provides structural support. - **Gelatin**: a denatured form of collagen, which offers cell-adhesive sites and mimics extracellular matrix (ECM) proteins. - **Hyaluronic acid (HA)**: a glycosaminoglycan present in the skin ECM, contributing to cell signaling and hydration. This combination—referred to as Alg/HA/Gel—was specifically designed to more closely resemble the human melanoma microenvironment by incorporating ECM-derived molecules (gelatin and hyaluronic acid) alongside alginate, which is commonly used for crosslinking and structural purposes. The inclusion of gelatin and HA supports mammalian cell anchorage, interaction, and remodeling, making the bioink more favorable for melanoma cell growth and behavior compared to more artificial matrices like pure alginate or nanocellulose-based bioinks [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2-3]. k12_paper: The primary components of bioinks developed to mimic the melanoma microenvironment are typically chosen to recapitulate the biochemical, structural, and mechanical properties of native skin and tumor tissue. According to the literature, the main components include: 1. **Natural Hydrogels**: These provide a supportive 3D matrix similar to the extracellular matrix (ECM) of skin and melanoma tissue. Commonly used hydrogels include: - **Collagen**: The main structural protein in skin ECM, supporting cell adhesion and migration. - **Gelatin**: A denatured form of collagen, often modified (e.g., GelMA) for improved printability and crosslinking. - **Hyaluronic Acid (HA)**: A glycosaminoglycan abundant in skin ECM, involved in cell signaling and migration. - **Alginate**: Used for its biocompatibility and ease of gelation, often combined with other polymers for improved cell interaction. - **Matrigel**: A basement membrane extract rich in ECM proteins and growth factors, commonly used to support melanoma cell growth and invasion [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2-3; Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 9-10]. 2. **Synthetic Polymers**: Sometimes included to tune mechanical properties or printability, such as: - **Polyethylene Glycol (PEG) or PEGDA**: For mechanical strength and tunable crosslinking. - **Pluronic F127**: Used as a sacrificial or support material [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 7-8]. 3. **Melanoma Cells**: The bioink is loaded with melanoma cell lines (e.g., A375) or patient-derived melanoma cells to model tumor behavior [Source: Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 14]. 4. **Stromal and Immune Cells**: To better mimic the tumor microenvironment, fibroblasts, endothelial cells, and sometimes immune cells are included, reflecting the cellular heterogeneity of melanoma [Source: 3D bioprinted breast tumor-stroma models for pre-clinical drug testing.pdf, Pages: 2, 9]. 5. **Growth Factors and Cytokines**: These may be incorporated or retained in ECM-derived materials (like Matrigel or decellularized ECM) to support cell proliferation, migration, and angiogenesis, which are critical in melanoma progression and metastasis [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 3, 7]. 6. **Decellularized Extracellular Matrix (dECM)**: dECM from skin or melanoma tissue can be used to provide a tissue-specific microenvironment, containing native ECM proteins and signaling molecules [Source: 3D bioprinted breast tumor-stroma models for pre-clinical drug testing.pdf, Pages: 5-6]. **Summary Table of Key Bioink Components for Melanoma Microenvironment:** | Component Type | Examples/Functionality | |-----------------------|---------------------------------------------------------------| | Natural Hydrogels | Collagen, Gelatin (GelMA), Hyaluronic Acid, Alginate, Matrigel| | Synthetic Polymers | PEGDA, Pluronic F127 | | Tumor Cells | Melanoma cell lines (e.g., A375), patient-derived cells | | Stromal/Immune Cells | Fibroblasts, endothelial cells, immune cells | | Growth Factors | VEGF, FGF, TGF-β (often present in Matrigel/dECM) | | dECM | Decellularized skin or melanoma ECM | **References:** - [A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 2-3, 7] - [Advanced tumor organoid bioprinting strategy for oncology research.pdf, Pages: 7-10, 14] - [3D bioprinted breast tumor-stroma models for pre-clinical drug testing.pdf, Pages: 2, 5-6, 9] In summary, the primary components of melanoma-mimicking bioinks are natural ECM-derived hydrogels (collagen, gelatin, hyaluronic acid, alginate, Matrigel), melanoma cells, stromal/immune cells, and sometimes synthetic polymers or dECM, all designed to recapitulate the biochemical and biophysical cues of the melanoma microenvironment. row 30 question: What biological behaviors of melanoma cells were investigated in relation to the viscoelastic features of the bioink? k1_paper: The study investigated several biological behaviors of melanoma cells in relation to the viscoelastic features of the bioinks: 1. **Proliferation and Dormancy**: The proliferation rate of melanoma cells (Mel Im cell line) was assessed in different bioinks. In Cellink Bioink, which has higher elasticity and lower cell-matrix interaction potential, melanoma cells exhibited a dormant-like state with reduced Ki67 expression, indicating low proliferation. In contrast, in Matrigel and Alg/HA/Gel (which allow more cell-matrix interaction), cells maintained high Ki67 expression and proliferated more actively. This demonstrates that the viscoelastic properties and composition of the bioink can induce either a proliferative or dormant phenotype in melanoma cells [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 7-8]. 2. **Tumor Growth In Vivo**: The ability of melanoma cells to form primary tumors in vivo was evaluated. Matrigel and Alg/HA/Gel, both with viscoelastic properties conducive to cell anchorage and remodeling, supported substantial tumor growth. In contrast, Cellink Bioink, with higher stiffness and less cell-adhesive properties, did not support significant tumor growth, further linking the viscoelastic and biochemical features of the bioink to tumor progression [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 8-9]. 3. **Migration and Matrix Remodeling**: The study also observed the ability of melanoma cells to migrate and remodel the matrix. In Matrigel, cells could migrate and spread, while in Alg/HA/Gel, they formed spherical colonies without spreading. In Cellink Bioink, due to its dense and less porous structure, cells could not migrate or remodel the matrix, remaining mostly dormant [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 7-8]. 4. **Metastatic Potential**: Despite the lack of primary tumor growth in Cellink Bioink, metastatic clusters were found in lymph nodes, indicating that even in a dormant-like state induced by the viscoelastic properties of the bioink, melanoma cells retained metastatic potential [Source: A vascularized in vivo melanoma model suitable for metastasis research of differ.pdf, Pages: 9-10]. In summary, the viscoelastic features of the bioink—such as stiffness, elasticity, and pore structure—were shown to significantly influence melanoma cell proliferation, dormancy, migration, matrix remodeling, and metastatic behavior in both in vitro and in vivo settings. k3_paper: The biological behaviors of melanoma cells investigated in relation to the viscoelastic features of the bioink included: 1. **Cell Survival and Proliferation**: The study evaluated how the viscoelastic properties of the alginate-cellulose (AlgCell) bioink influenced the survival and proliferation of melanoma cells. It was found that the pore size and viscoelasticity of the bioink allowed for sufficient nutrition supply and cell movement, supporting cell viability and proliferation within the 3D environment [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 1-14]. 2. **Cell Cycle State**: Using FUCCI-labelled melanoma cells, the researchers monitored the distribution of cells in different phases of the cell cycle (G1, S, G2/M) within the bioink. This allowed them to assess how the mechanical environment affected cell cycle progression and potential dormancy or proliferation states [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 5-8]. 3. **Tumor Spheroid Formation and Stability**: The ability to print and maintain stable tumor spheroids in the AlgCell bioink was assessed. The viscoelastic and structural properties of the bioink supported the formation and maintenance of spheroids, which are more representative of in vivo tumor architecture [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 8-10]. 4. **Cell Migration and Invasion**: The study specifically investigated the migratory behavior of melanoma cells and spheroids in different bioink formulations. Multiphoton microscopy revealed that, after 7 days of cultivation, individual melanoma cells left the tumor spheroid and invaded the surrounding microenvironment, indicating that the viscoelastic and porous nature of the AlgCell bioink permitted cell movement and invasion [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 8-12]. 5. **Morphology and Interaction with the Matrix**: The interaction between melanoma cells and the bioink matrix was analyzed using SEM and multiphoton microscopy. The results showed that the viscoelastic features and pore structure of the bioink influenced cell morphology, spreading, and the ability to migrate through the matrix [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 5-8, 10-12]. In summary, the study demonstrated that the viscoelastic features of the AlgCell bioink significantly influenced melanoma cell survival, proliferation, cell cycle progression, spheroid stability, migration, invasion, and interaction with the matrix, thereby mimicking key aspects of the tumor microenvironment relevant to melanoma progression and metastasis. k6_paper: The biological behaviors of melanoma cells investigated in relation to the viscoelastic features of the bioink included: 1. **Cell Survival and Proliferation**: The studies assessed how the viscoelasticity of the alginate-cellulose (AlgCell) bioink affected the viability and proliferation of melanoma cells (Mel Im and MV3 cell lines) after printing. High cell viability was observed in AlgCell, and cell cycle progression was monitored using FUCCI-labeled cells to distinguish between proliferative and non-proliferative states [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 5-6]. 2. **Tumor Spheroid Growth and Invasion**: The ability of melanoma spheroids to grow and invade the surrounding matrix was evaluated. In AlgCell bioink, spheroids maintained their structure and showed single-cell migration into the matrix, while in pure alginate, more collective invasive growth was observed. This suggests that the viscoelastic properties and pore structure of the bioink modulate the mode of invasion (single-cell vs. collective) [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 9-10]. 3. **Cell Migration**: The random distribution of cellulose fibers and the interconnected pore network in AlgCell allowed individual melanoma cells to leave the spheroid and migrate into the microenvironment. This migration was visualized using multiphoton microscopy and SEM, indicating that the viscoelastic and structural properties of the bioink support cell movement [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 6, 9-10]. 4. **Cell Cycle State**: Using FUCCI-labeled melanoma cells, the studies monitored the distribution of cells in different phases of the cell cycle within the viscoelastic bioink. The cell cycle state was influenced by the microenvironment provided by the bioink, with differences in proliferation rates observed between alginate and AlgCell [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 5-6]. 5. **Morphology and Spheroid Integrity**: The morphology of melanoma cells and the integrity of spheroids were assessed in relation to the bioink's viscoelasticity. In AlgCell, spheroids remained intact with viable, densely packed cells, and individual cells could be observed migrating away from the spheroid, indicating that the bioink's mechanical properties support both spheroid stability and cell dissemination [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 9-10]. In summary, the viscoelastic features of the bioink were shown to influence melanoma cell survival, proliferation, migration, invasion mode (single-cell vs. collective), cell cycle state, and spheroid integrity, demonstrating the importance of bioink mechanics in modeling tumor biology [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 5-10]. k12_paper: The biological behaviors of melanoma cells investigated in relation to the viscoelastic features of the bioink include: 1. **Cell Survival and Proliferation**: The study evaluated the survival and proliferation of melanoma cells (specifically Mel Im and MV3 cell lines) within 3D-printed constructs using an alginate-cellulose (AlgCell) bioink. The bioink was designed to mimic the viscoelasticity of the dermal microenvironment, and the impact of these mechanical properties on cell viability and proliferation was assessed [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 1-14]. 2. **Cell Cycle and Dormancy**: Using FUCCI-labeled melanoma cells, the researchers monitored cell cycle progression within the bioink. They observed that the viscoelastic properties of the AlgCell bioink influenced the proportion of cells in different cell cycle phases, with implications for dormancy and proliferation [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 1-14]. 3. **Cell Migration and Invasion**: The study examined the migratory behavior of melanoma cells and spheroids embedded in the AlgCell bioink. Multiphoton microscopy and SEM revealed that the viscoelastic and porous structure of the bioink allowed individual melanoma cells to leave the spheroid and invade the surrounding matrix, reflecting in vivo-like invasive behavior [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 1-14]. 4. **Colony and Spheroid Formation**: The ability of melanoma cells to form colonies and spheroids within the viscoelastic bioink was assessed. The bioink’s pore size and mechanical properties supported the formation and maintenance of 3D tumor spheroids, which are more representative of in vivo tumor architecture than 2D cultures [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 1-14]. 5. **Phenotypic Plasticity and Invasion Mode**: The study noted that the viscoelastic features of the bioink influenced the mode of invasion—favoring single-cell migration over collective migration, depending on the matrix structure and stiffness. This is relevant for modeling metastatic behavior and tumor progression [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 1-14]. In summary, the viscoelastic features of the bioink were shown to modulate melanoma cell viability, proliferation, cell cycle state, migration/invasion, and the formation of 3D tumor-like structures, thus providing a more physiologically relevant model for studying melanoma biology and therapeutic responses [Source: An alginate-cellulose based bioink mimics the viscoelastic features of the melan.pdf, Pages: 1-14].